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Deanna Belsky, Ph.D.
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Amyotrophic Lateral Sclerosis is a neurodegenerative disorder characterized by
progressive muscle denervation, motor axon degeneration and the death of
motor neurons. The molecular mechanisms that mediate axon degeneration in
ALS remain unknown, but motor neuron cell body death occurs through
apoptosis. Genetic deletion of the pro-apoptotic gene Bax delays muscle
denervation, prolongs disease onset, prevents motor neuron cell death and
improves survival in an ALS mouse model. However, the timing and extent of
axon degeneration in these mice is unaffected. Here, we examine the role of
Sarm1, a component of the Wallerian degeneration pathway, and its interaction
with the classical apoptotic cascade in ALS. Consistent with previous work, we
find that genetic deletion of Bax delays symptom onset and extends lifespan of
SOD-1G93A transgenic mice. In contrast, elimination of Sarm1 modestly delays
axon degeneration at later stages of the disease without affecting lifespan.
Genetic block of both pathways delays symptom onset, prolongs survival, and
decreases disease burden by significantly reducing, by half, the number of days
that mice exhibit disease-related symptoms. Our results demonstrate divergent

and mutually reinforcing roles for the apoptotic and Wallerian degeneration
pathways in ALS and suggest the presence of a molecularly distinct pathway that
mediates disease progression.
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Chapter 1: Introduction and Overview of the Field
Rationale
Neurodegenerative disorders are characterized by the disruption and
death of neuronal cells. Different neurodegenerative diseases result in a loss of
distinct neuronal cell types, particularly in their early stage. For example,
Alzheimer’s disease is mainly characterized by the loss of cortical neurons,
Parkinson’s affects dopaminergic neurons in the substantia nigra, Huntington’s
causes death of striatal neurons in the basal ganglia, and amyotrophic lateral
sclerosis (ALS) is specific to motor neurons and corticospinal neurons. While
different neuronal cell types are affected, there is evidence that similar cell death
pathways are active during degeneration in these unique diseases. In this study,
we will focus on neuronal cell death of motor neurons in ALS, but hope that
elucidation of these cell death mechanisms may be applied more broadly to
neuron degeneration in neurodegenerative diseases, in general.
Amyotrophic Lateral Sclerosis (ALS) is a fatal disorder that results in
degeneration of motor neurons located in the brain and spinal cord, which leads
to paralysis and eventual death. Studies have described ALS as a “dying back”
disorder, which begins with disruption in synaptic connections at the
neuromuscular junction, followed by axon degeneration resulting in motor neuron
cell death (Fischer et al, 2004). While the anatomical features of the disease
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have been well documented, the underlying molecular mechanisms remain
unknown.
Since axon degeneration precedes motor neuron loss, we thought by
targeting mechanisms of axon degeneration we might be able to delay onset or
prevent disease progression in an ALS mouse model. The work in this thesis
examines an approach to target an axon degeneration mechanism known to be
involved in other motor neuronopathies that is distinct from other cell death
pathways. Since it is already known that the apoptotic pathway is involved in
ALS, we further attempt to elucidate the interaction of these two pathways in a
murine model of ALS.

Amyotropic Lateral Sclerosis Prevalence and Types
Amyotrophic Lateral Sclerosis (ALS), sometimes referred to as Charcot’s
sclerosis (named after Jean-Martin Charcot who discovered the disease) or Lou
Gehrig’s disease, is a rapidly-progressing adult-onset neurodegenerative
disorder characterized by degeneration of upper and lower motor neurons, which
leads to paralysis and eventual death (Cleveland and Rothstein, 2001) (Figure
1.1). ALS has a prevalence of about 2 per 100,000 total cases each year
(O’Toole et al, 2004), with multiple studies showing an increased risk in males
(Vazquez et al, 2008). The average age of onset for a typical ALS patient is
between 50-65 (Logroscino et al, 2008; O’Toole et al, 2008) and progression of
the disease is typically very rapid with the time from disease onset until death
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ranging from three to five years. While most cases of ALS have a late onset and
fast progression, 5% of cases are juvenile forms where onset occurs much earlier
between the ages of 20-40 (Andersen et al, 2011). These juvenile cases usually
progress more slowly from onset until death and predominantly affect so called
upper motor neurons (i.e., corticospinal tract neurons, with cell bodies in layer V
of the cortex) (Pupillo, et al, 2014; Zoccolella et al, 2008; Sabatelli et al, 2008).
About 10% of ALS cases are inherited as an autosomal dominant trait
(Leblond et al, 2014; Sreedharan et al, 2013) with the remaining 90% caused by
sporadic mutations. Familial ALS (fALS) and sporadic ALS (sALS) both have
similar pathological hallmarks (Boillée et al, 2006; Ferraiuolo et al, 2011)
including progressive muscle weakness, atrophy, and spasticity (Amato et al,
2008) with denervation of the respiratory muscles as the fatal event for most
patients. The type of mutation does seem to affect the site of onset of the disease
with some sites resulting in a more aggressive form of ALS. For example, ALS
patients with onset in the bulbar muscles have a mean survival of 2 years (Chiò
et al, 2011). This shows that some patients do have a genetic component,
however pathology at autopsy is very similar in ALS patients with different
mutations (Iwanaga et al, 1997).
Patients with either fALS or sALS can develop frontotemporal lobar
dementia (FTLD) as well. FTLD is characterized by degeneration of layer V
neurons located in the frontotemporal lobe of the cortex, which results in
behavioral changes (Figure 1.1). 25% of patients with ALS display clinical FTD
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(Swinnen, et al 2014) through language abnormalities, disinhibition, delusions
(Strong et al, 2011; Mioshi et al, 2014), and depression (although whether
depression is caused by cognitive changes or reactive depression is difficult to
tell) (Ferrari et al, 2011).

Figure 1.1 Illustration of areas affected in ALS. Upper motor neurons (UMN)
(in blue) and lower motor neurons (in red) are the areas affected in both familial
and sporadic ALS. 25% of these cases are associated with degeneration in layer
V of the frontotemporal lobe (in orange). Degeneration of each of these
components causes different phenotypes listed in the blue box for UMN
degeneration and the orange box for LMN degeneration (Swinnen, et al 2014).
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Genetic and molecular underpinnings of ALS
Over the past few years, great progress has been made in determining the
genetic etiology of ALS, which has in turn led to insights into molecular
mechanisms of neurodegeneration. ALS was thought initially to be a nonhereditary disease. It wasn’t until 1955 that a hereditary form was identified
(Kurland and Mulder 1955). As mentioned above, 10% of ALS cases have been
identified as familial with the rest labeled as sporadic, but in part caused by
identifiable mutations. Currently, the genetic etiology of two-thirds of fALS and
11% of sALS are known to be caused by genetic mutations (Figure 1.2).

Fig 1.2 Mutations that cause familial and sporadic forms of ALS. Genes with
mutations found to cause familial (top circle) or sporadic (bottom circle) forms of
ALS. Each color identifies one gene including C9ORG72 (green), FUS (light
blue), TARDBP (dark blue), SOD-1 (purple), other genes that contribute including
OPTN, VCP, SQSTM1, PFN1, UBQLN2 (yellow) and unknown (red). The number
in the middle of the circle represents the total fraction of either fALS or sALS
cases (Renton et al, 2014).
5

The first gene mutation identified in an ALS patient was in the superoxide
dismutase-1 (SOD-1) gene (Rosen et al, 1993). The next gene, TARDBP, was
not identified until fifteen years later (Sreedharan et al, 2008). Advances in
technology and computation, such as GWAS studies, have led to the discovery of
many more contributing genes in recent years, including fused in sarcoma (FUS),
valosin-containing protein (VCP), optineurin (OPTN), ubiquilin 2 (UBQLN2),
sequestosome 1 (SQSTM1) and a hexanucleotide repeat expansion in C9ORF72
(Kwiatkowski et al, 2009; Vance et al, 2009; Johnson et al 2010; Renton et al
2011; DeJesus-Hernandez et al, 2011; Maruyama et al, 2010) (Figure 1.2 and
Table 1.1).
Table 1.1 Genes known to carry ALS-causing mutations. Genes identified to
be mutated in ALS (first column), location of gene on the chromosome (second
column), how the gene is inherited as autosomal dominant (AD), autosomal
recessive (AR) or X-linked dominant (XD) (third column), percentage of cases in
which this gene has been shown to cause either fALS or sALS (fourth and firth
column, respectively), and putative protein function (sixth column) (Renton et al,
2014).
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Other genes have also been identified in rare cases to cause ALS or ALS-like
pathology (Hadano et al, 2001; Eymard-Pierre et al 2002; Chen et al, 2004;
Duqette et al, 2005) (Table 1.2).

Table 1.2 Other genes implicated in the pathogenesis of ALS. Multiple
additional genes have been reported with rare mutations that can cause ALS.
Most of these mutations cause a juvenile onset, slower progressing version of the
disease. Column labels are similar to Table 1.1 and listed in above legend.
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Some commonalities between protein function of mutated genes in ALS
have been found, such as RNA metabolism dysfunctions in the TARDBP and
FUS genes, proteasome and vesicle transport defects in VCP, OPTN and
UBQLN2, and axonal transport and vesicle trafficking defects in various slow
progressing and juvenile onset forms, but there does not seem to be one
overarching theme of protein function that is deregulated in motor neuron
degeneration in ALS, since many different types of dysfunctions can cause ALS
symptoms.

SOD-1 function and mutations
As mentioned above, the first gene mutation identified to cause familial
ALS was in the gene encoding superoxide dismutase 1 (SOD-1) (Rosen et al,
1993). 20% of the 10% of fALS cases have been attributed to SOD-1, making up
2-5% of all ALS cases. SOD-1 encodes a cytosolic, Cu/Zn-binding protein that
catalyzes the conversion of toxic superoxide O2- to O2 and H2O2 (Fridovich,
1976). SOD-1 is located in the cytosol, nucleus, peroxisomes, and mitochondrial
intermembrane space (Fridovich I, 1997; Okado-Matsumoto et al, 2001; Sturtz
LA et al, 2001).
Although the function of SOD-1 is known, it has been very difficult to
determine the nature of its dysfunction in ALS. This is because over 100 different
mutations have been identified in the SOD-1 gene to cause ALS (Valentine et al,
2004), but these mutations vary in biochemical properties, stability, and protein

8	
  

function (Hayward et al, 2002; Rodriguez et al, 2002; Tiwari et al, 2003). Mutated
sites include positions in the metal-binding ligand or electrostatic loop that might
perturb metal binding affinity, positions at the disulfide bond where protein
stability might be affected, and truncations that would not allow dimerization to
occur. On the other side of the spectrum, many SOD1 mutations occur in
locations far away from critical areas of protein function. Some of the mutant
forms of SOD-1 retain nearly normal SOD1 activity. It is therefore thought that
mutant SOD-1 exerts its effect through a gain of function mutation. This
conclusion is further supported by a lack of an ALS phenotype in SOD-1 deficient
mice (Reaume et al, 1996) or mice overexpressing human wild-type SOD-1
(Gurney et al, 1994).
Mutations that affect different SOD1 functions also do not correlate with
survival times. Mutations in human SOD1 that result in an activity similar to WT
SOD1 show a greater than seventeen-year survival for G37R, G41D, and E100K,
about ten year survival for G93C, about five years for E100G, one to three years
for L38V, H43R, and G93A, and one year for A4V (Orrell et al, 1999; Parton et al
2002). Mutations in SOD1 found in the metal binding region have similar
variability with a greater than seventeen-year survival for H46R (Abe et al, 1996),
six years for G85R (Juneja et al, 1997), and very short survival times for H48Q
and S134N.
Information on how mutations in SOD1 affected its activity levels came
from studies in yeast. Human WT SOD1 and multiple SOD1 mutant proteins,
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including A4V, G37R, L38V, G41D, G85R, G93A, G93C, and I113T, rescued the
O2- negative phenotype of the sod1Δ yeast strain (Rabizadeh et al, 1995; Corson
et al, 1998). H46R and H48Q mutant SOD1 did not rescue this phenotype
(Ratovitski et al, 1999), indicating that SOD-1 activity is not the cause of the ALS
phenotype.
There is some evidence that mutated SOD-1 protein aggregates in ALS,
which is similar to what is seen in other neurodegenerative disorders, such as aβ
plaques in Alzheimer’s disease and Lewy bodies in Parkinson’s disease (Soto et
al, 2003; Valentine et al, 2003). Mutated SOD-1 human patient samples have
been found to have inclusions containing neurofilament, ubiquitin, and SOD1
protein aggregates. These protein aggregates are not thought to be toxic since
accumulation occurs during late stages of the disease (Morrison et al, 1998).
However, high molecular weight oligomers of SOD1 are found well before
disease onset in mice expressing mutant SOD1 so this evidence does indicate
that mutant SOD1 does differ in some feature from its wild type form to allow for
oligomerization (Wang et al, 2002; Johnston et al, 2000).

SOD-1 transgenic mouse models to study ALS
Multiple mutant SOD-1 transgenic mouse models have been created that
reproduce the human disease phenotype (Wong et al, 1995; Bruijn et al, 1997;
Ripps et al, 1995; Brännstöm et al, 2000). Transgene copy number of mutated
SOD-1 has been found to be important in determining disease phenotype. High
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transgene copy number causes early onset and a rapidly progressive disease,
whereas low transgene number causes a late onset and a slower progressing
form (Dal Canto et al, 1995; Dal Canto et al, 1997). Three well-characterized
transgenic SOD1 mutant lines are the G93A (Nagai et al, 2001), G37R (Wong et
al, 1995) and the G85R (Bruijn et al, 1997) mutation, each expressing a high
transgene copy number.
Although disease onset and survival vary among transgenic mouse
strains, many pathological features remain constant and comparable to ALS
patients. Hind limb weakness and tremors usually occur at symptom onset,
followed by progressive motor paralysis and eventually death. The early onset,
fast progressing transgenic mouse model, SOD1G93A, dies around four to five
months. The gray matter of the motor neuron system is most dramatically
affected in mutant SOD1 trangenic mice, specifically the ventral horn and
brainstem motor nuclei, which are not affected in non-transgenic or WT SOD-1
overexpressing mice (Wong et al, 1995; Brujin et al; 1997; Ripps et al 1995;
Gurney et al 1994; Friedlander et al 1997). In transgenic mice with high SOD-1
copy number, lesions have also been seen to extend into other areas such as the
dorsal horn of the spinal cord, vagal nerve dorsal nuclei, brainstem reticular
formation, substantia nigra, cerebellum, and thalamus.
Numerous malfunctions of various biological processes have been
identified in ALS mouse models including protein aggregations, mitochondrial
abnormalities, axonal transport dysfunction, dysregulation of calcium metabolism,
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high glutamate levels, and oxidative damage (Brujin et al, 2004, Ilieva et al, 2007,
Lev et al, 2009). Interestingly, the morphological changes in lower motor neurons
seem to occur in a “dying back” fashion in mice (Frey et al, 2000). This
phenotype is manifested through weakening at the synapse, followed by axon
degeneration, which precedes motor neuron cell body loss. This phenomenon is
not unique to ALS, since this type of disease progression is also seen in
progressive motor neuropathy mouse models (Schmalbruch et al, 1991). Studies
have elucidated similar spatiotemporal progression of the disease in an
SOD1G93A transgenic ALS mouse model (Fischer et al, 2003).
It has been well reported that a pathological phenotype precedes disease
onset. Fischer et al. (2003) discovered that neuromuscular junction (NMJ)
denervation begins at day 47, while clinical stages of the disease do not occur
until day 80. This study also pointed out that ventral root motor axons were
affected between these two timepoints and a loss of alpha motor neurons (the
vulnerable subtype of motor neurons in ALS) did not occur until day 100 (Figure
1.3). This same study also analyzed a 58-year-old ALS patient who died
unexpectedly before undergoing full progression of the disease. Samples from
this patient showed atrophy in leg muscles, but very little axon degeneration.
Also, motor neuron number in the spinal cord was normal. This case is anecdotal
and therefore cannot be used to generalize a common pathology in mice and
humans, but is an indication that something similar might be occurring.
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Fig 1.3 Histological analysis of SOD-1G93A Tg mouse model throughout
disease progression. A) Percentage of neuromuscular junction innervation
(white), partially innervated (gray), and denervated (black) at various timepoints
throughout disease. B) Percentage of axon degeneration at various timepoints.
C) Number of neuron cell bodies in the ventral horn at various timeopints. Red
boxes indicate the timepoint where significant loss is seen of each parameter
(Fischer et al, 2003).

Other groups went on to characterize the loss of neuromuscular junction
innervation in more detail. The hindlimb muscles are dramatically affected at
early stages and throughout the disease and are therefore the major site
analyzed in many studies. The mouse hindlimb contains three major muscles that
have been analyzed extensively. These include the gastrocnemius, the tibialis
anterior, and the soleus muscles. Each of these muscles contains a different
composition of fast and slow twitch fibers. The gastrocnemius and tibialis anterior
muscles are composed mostly of fast twitch fibers, referred to as Type IIB fibers.
The soleus muscle is made up mostly of slow fibers, or Type IIA fibers.
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Identification of a third category of muscle, the Type IID fibers, is intermediate
between the fast and slow fibers. Fast fibers rely on more glycolytic mechanisms
for metabolism, while slow fibers use oxidative mechanisms. Type IID fibers use
a combination of both of these mechanisms, but are still categorized as fast
fibers.
EMG recordings of whole muscle and motor unit contractile forces were
taken from both fast and slow muscle fibers at different timepoints in a
SOD1G93A transgenic mouse model (Hegedus et al, 2007). They found that
there was an initial loss of fast motor unit function, but not slow motor units. Slow
motor unit loss occurred later and the loss of overall motor units in the hind limb
plateaued during symptomatic stages of the disease. These results are
consistent with immunohistochemical evidence showing that denervation occurs
in a muscle specific manner. This makes sense since fast motor units innervate
fast muscle fibers and slow motor units innervate slow muscle fibers.
It is thought that clinical symptoms occur after denervation due to the
ability of the remaining axons that innervate slow fibers to reinnervate muscle
fibers through collateral sprouting. Motor axons that innervate fast fibers, the
most vulnerable type, are not able to sprout and reinnervate target muscles,
while the axons that innervate slow fibers retain this ability (Frey et al, 2000).
Compensatory sprouting occurs until a critical point is reached where
reinnervation is unable to substitute for the increased denervation, which is when
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muscle weakness or symptomatic stages of the disease occur (Felice et al, 1997;
Hayworth et al, 2009).
It has been shown that large caliber axons are the most susceptible in an
SOD1G93A mouse model (Feinberg et al, 1999, Bendotti et al, 2001, Fischer et
al, 2003). Others have provided further insight into the mechanisms underlying
this vulnerability (Pun et al 2006). The large size of the axons might indicate a
greater dependency on axonal transport. This is consistent with studies that
show perturbations in various axonal transport proteins can cause symptoms of
ALS in motor neuron diseases and have also been identified in the SOD1G93A
mouse, specifically neurofilament aggregates. Other studies have shown
enlarged mitochondria in the distal part of large axons in the sciatic nerve of the
SOD1G93A mouse at presymptomatic stages of the disease and in sporadic ALS
patients (Siklos et al, 1996, Dadon-Nachum et al, 2011).
Multiple studies identify synapses at the NMJ as a vulnerable location for
motor neuron axons. A few hypotheses currently exist, but no one abnormal
function has been attributed to synaptic dysfunction leading to axon
degeneration. Some information is known about the mechanisms of cell body
loss following axon degeneration, which will be discussed in later sections.

Cell autonomous mechanisms in ALS
Descriptive studies examining the anatomical features of motor neuron cell
death in the mutant SOD-1 disease mouse model led many to believe that the
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disruption was occurring in neuronal cells. The first evidence that mutant SOD-1mediated cell death was not solely neuronal came from evidence where human
mutant SOD-1 was expressed exclusively in motor neurons, but did not cause
ALS symptoms (Pramatarova et al, 2001). The SOD-1G37R high transgene copy
number was driven under the neurofilament promoter and although mutant SOD1 expression was high in motor neurons in the spinal cord, no cell body loss in
the spinal cord or axon degeneration in the ventral root was observed. In
addition, there was no effect on motor performance when testing motor function
using the limb grip strength test.
Other work pointing to a non-cell autonomous component driving ALS was
work from Clement et al, who showed that the ALS phenotype observed in the
SOD-1 mutant mouse was driven by a combination of cell autonomous and noncell-autonomous processes. In this study, researchers created mutant SOD-1
chimeric mouse lines that express both mutant SOD-1 and WT cells and showed
that non-mutant SOD-1 motor neurons develop an ALS pathology, specifically
SOD-1 aggregate and ubiquitin accumulation, which causes these WT cells to
atrophy. This group also went on to show that nonneuronal non-mutant SOD-1
cells can delay or prevent degeneration of ventral root axons and motor neuron
loss in the spinal cord and ultimately result in an extended lifespan in these
chimeric lines compared to SOD-1 mutant lines (Figure 1.4) (Clement et al,
2003).
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Fig 1.4 ALS includes cell autonomous and non-cell autonomous
mechanisms. A) Chimeric SOD1G85R and SOD1G37R mutants were created by
injecting WT YFP expressing ES cells into SOD1G85R and SOD1G37R mutant
animals at the blastocyst stage. B) Survival curve showing extended survival in
chimeras vs. mutant SOD-1 lines. C) Number of neurons in ventral spinal cord
per field quantified for WT, SOD-1G37R, and two chimeric lines (#646 and #213)
where the left side contained WT expressing YFP cells and the right side did not.
Representative image of D) motor axons in ventral root of chimeric line #646
showing degeneration in right side without WT expressing-YFP cells and E)
motor neurons in spinal cord degenerated without WT non-neuronal cells
present. (Clement et al, 2003)
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Since this finding, other groups have tried to identify the source of the noncell autonomous toxic effect. There are conflicting results in the field as to what is
the driving factor that causes SOD-1 mediated toxic cell death. Nagai et al
isolated conditioned medium from mutant SOD-1 astrocytes and found it to cause
primary motor neuron cell death (Nagai et al, 2007). Other labs have identified
microglia as the major contributor to motor neuron cell death in vitro (Fig 1.5) (de
Boer et al, 2014).

A

C

B

Figure 1.5 The role of non-cell autonomous mutant SOD-1 on motor
neurons in vitro. A) Isolation and identification of motor neurons through Hb-9GFP and ChAT staining. B) Conditioned medium from mutant SOD-1 astrocytes,
but not any other cell type shows motor neuron cell death. C) Another study
shows motor neurons cultured with mutant SOD-1 microglia (bottom panel) have
an even greater cell death effect than when cultured with mutant SOD-1
astrocytes (top panel). Red bar = SOD-1G93A treated, White bar = Non-transgenic
treated (Nagai et al, 2007 A, B; de Boer et al 2014 C). PMN = primary motor
neuron
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Mechanisms of Apoptosis
The apoptotic pathway involves a complex series of steps that can be
activated through multiple avenues. Apoptosis can proceed through the death
receptor (extrinsic) or the mitochondrial (intrinsic) pathway (Figure 1.6). The
death receptor mediated pathway can be initiated through ligand binding to
receptors such as Fas/CD95 and tumor necrosis factor receptor 1 (TNFR1). This
binding allows these receptors to aggregate “death domains” intracellularly that
can then aggregate adaptor proteins, Fas associates with FADD and TNFR1
associates with FADD and TRADD. FADD and TRADD contain death domains,
which are then able to recruit and activate pro-caspase 8 (Vila and Pzedborski
2003).
The mitochondrial or intrinsic pathway can be activated through a death
receptor-independent mechanism. Various stimuli trigger translocation of proapoptotic effectors including Bax and its relative Bak, to the mitochondria. Bax
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and Bak localize to the mitochondrial outer membrane to allow for
permeabilization and subsequent release of cytochrome c into the cytosol.
Cytochrome c is then able to interact with other proteins, specifically procaspase
9 and Apaf1 (Li et al, 1997) leading to the cleavage and activation of the initiator
caspase, Caspase-9 (Hengartner et al, 2000). Catalytically active caspase-9 can
then further activate downstream effector caspases, such as caspase-3 and -7
(Liu et al, 1997; Sakahira et al, 1998). Caspase-3 is the first step in the pathway
that can both be activated by the intrinsic and extrinsic pathways.
In addition to activators of apoptosis, there are also known inhibitors and
modulators of the apoptotic pathway. A well-known family of proteins that can
inhibit apoptosis are the pro-survival Bcl-2 family members. This group consists
of Bcl-2, Bcl-xL, Bcl-w, Mcl1, Bcl-B, and A1. There are also a group of proapoptotic family members including Bad, Bim, Bid, Hrk, Noxa, Puma, and BMF
(Figure 1.6) (Adams and Cory, 1998; Youle and Strasser, 2008). The pro-survival
family members, such as Bcl-2 and Bcl-xL have been shown to inhibit Bax and
Bak by direct binding (Willis et al, 2007).
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Figure 1.6 Apoptotic Pathway Schematic. The apoptotic pathway can either be
initiated through the death receptor-mediated (extrinsic) or the mitochondrial
(intrinsic) pathway. Both lead to downstream activation of effector caspases. The
intrinsic pathway can be initiated through a number of different stress signals,
which lead to colocalization of Bax and Bak to the mitochondria. This results in
outer membrane permeabilization and release of cytochrome c into the cytosol.
Pro-caspase-9 is then cleaved to its active initiator caspase-9 form which can
then cleave downstream effector caspases such as Caspase-3 and -7 (Illustrated
by David Simon).
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The role of the apoptotic pathway in ALS
There is increasing evidence to suggest that motor neuron degeneration in
ALS occurs at least partly by a programmed cell-death mechanism (PCD). The
initial evidence that led investigators to believe that apoptosis plays a role in ALS
came from observations in vitro of transfected neuronal cells expressing mutant
SOD1 (Rabizadeh et al, 1995) and primary neurons grown from mutant SOD1
transgenic mice (Ghadge et al, 1997) dying by apoptosis. Cells undergoing
apoptosis have unique changes that occur including plasma membrane blebbing,
contraction of cytoplasmic organelles and chromatin condensation and
fragmentation. Interestingly, dying neurons in mutant SOD1 transgenic lines
exhibit some of the attributes of apoptosis such as the condensed chromatin, but
overall the morphology is indicative of a nonapoptotic mechanism that closer
resembles autophagy or necrosis (Clarke, 1999).
There are conflicting results regarding another key feature of apoptosis,
that is, fragmentation of DNA. One study observed differences in DNA
fragmentation in ALS patients vs. controls, but these studies were unable to be
replicated in either ALS patients or animal models (Yoshiyama et al, 1994, Martin
et al 1999, Migheli et al, 1999, Migheli et al, 1994, He et al, 2000). In determining
the PCD mechanism, it is common that the morphology of cells lie on a spectrum,
therefore a possibility is that multiple PCD pathways may be involved in ALS
since the morphology of dying motor neurons does not exactly replicate
traditional apoptotic morphology.
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While the morphological data of whether apoptosis is involved in ALS is a
little ambiguous, there are other more solid approaches that have been explored
in determining the apoptotic pathway’s role in ALS. One such approach is looking
at expression or through genetic manipulation of apoptotic factors in mutant
SOD1 mouse models.
Vukosavic et al showed that Bcl-2 and Bcl-xL (two anti-apoptotic family
members) had decreased expression levels at endstage of the disease
compared to earlier asymptomatic stages and non-transgenic animals (Fig 1.7)
(Vukosavic et al, 2000). Further evidence supporting the role of Bcl-2 in ALS is
seen by delayed symptom onset and extended survival in a mutant SOD-1
transgenic animal overexpressing bcl-2 (triangles in Figure 1.7) (Kostic et al,
1997).
Initiators of apoptosis were also found to play a role in ALS mouse
models. Bax, a component of the apoptotic pathway that can be triggered by
stress signals, has also been shown to be upregulated in an ALS mouse model
at endstages of the disease compared to asymptomatic stages or in nontransgenic animals (Fig 1.8A) (Vukosavic et al, 1999). Another group examined
further the localization of Bax and found that cytosolic Bax levels decreased at
endstages of the disease (Fig 1.8B), while mitochondrial levels of Bax increased
at endstages (Guegen et al, 2001) (Fig 1.8C). Since Bax is known to localize to
the mitochondria in order to permeabilize the outer membrane to initiate
apoptosis, this evidence supports an active role of Bax in apoptosis in an ALS
mouse model. In addition other groups have shown this effect through a
decreased ratio of anti apoptotic factors/Bax in ALS transgenic lines (Ekegren et
al, 1999; Gonzalez et al, 2000).
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Fig 1.7 The role of anti-apoptotic factors in a mouse model of ALS. A) The
age of onset is delayed and B) survival extended in a SOD1G93A/bcl-2
overexpressing (triangles) animal vs. SOD1G93A/- (circles) animal (Kostic et al,
1997). C) Endogenous levels of anti-apoptotic factors such as Bcl-2 and Bcl-xL
are reduced at endstages of the disease compared to asymptomatic and nontransgenic animals (Vukosavic et al, 2000).

All of these results were established in an SOD1G93A transgenic mouse
model, but it should be noted that Bax levels have also been shown to increase
and anti apoptotic factors shown to decrease at endstages of the disease in other
mutant SOD1 transgenic animals, such as the SOD1G86R mouse model of ALS
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(Gonzalez et al, 2000). The strongest evidence for Bax involvement in ALS is
seen through a genetic deletion of Bax in the SOD1G93A mouse line. SOD1/Bax
KO animals show a small extension in survival (Fig 1.8D) and better motor
performance on the rotorod (Fig 1.8E) (Gould et al, 2006).
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Fig 1.8 The role of Bax in an SOD1G93A mouse model of ALS. A) Endogenous
levels of Bax increase at endstage of the disease compared to asymptomatic and
non-transgenic animals. Further characterization of Bax expression shows that
B) cytosolic Bax decreases at endstage while C) mitochondrial Bax expression
increases. A genetic deletion of Bax in a SOD1G93A mouse model of ALS
(triangles) compared to Bax WT (squares) shows a D) 20 day extension in
lifespan and E) increased motor performance on the rotorod. AS =
Asymptomatic, BS = Beginning of symptoms, ES = Endstage, M = Month
(Vukosavic et al, 1999: panel A; Guegen et al, 2001: panel B, C; Gould et al,
2006: panel D, E)
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In addition to these upstream apoptotic factors, there is also evidence for
involvement of execution components of the apoptotic pathway. As mentioned
above, Bax/Bak colocalization at the mitochondria causes permeabilization of its
outer membrane, thus resulting in release of cytochrome c. At endstage (ES) of
an SOD1G93A mouse model, cytochrome c is shown to shift from the mitochondria
to the cytosol (Fig 1.9A) (Guegen et al, 2001). Evidence from other groups has
shown that minocycline (an inhibitor of cytochrome c release) is able to delay
progression of ALS (Zhu et al, 2002). Cytochrome c release allows for the
activation of the apoptosome and subsequent cleavage and activation of the
initiator caspase, Caspase-9. At endstages in ALS mice, cleavage of
Procaspase-9 to its catalytically active form is observed (Fig 1.9C) (Guegen et al,
2002).
Downstream effector caspases, caspase-3 and caspase-7 are then
subsequently cleaved at late stages of the disease (Fig 1.9D&E) (Li et al, 2000,
Guegen et al, 2001). Lastly, a known inhibitor of caspases, XIAP has been
shown to be cleaved to its inactive form at late stages of the disease (Fig 1.9B)
(Guegen et al, 2001). XIAP is the most potent inhibitor of apoptosis found in the
IAP family (Deveraux and Reed, 1999) and has been implicated in other
neurodegenerative diseases (Xu et al, 1999). Together, these results provide
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strong evidence for the role of the apoptotic pathway in transgenic mouse models
of ALS.
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Fig 1.9 Evidence for involvement of downstream executors of apoptosis in
ALS mouse models. A) Evidence of increased cytosolic cytochrome c and
decreased mitochondrial cytochrome c at endstage of the disease. B) Cleavage
of XIAP, a potent inhibitor of apoptosis, into its inactive form at endstages of the
disease. C) Activation from inactive procaspase-9 to the catalytically active form
of caspase-9 at endstages of the disease. D) Cleavage of Caspase-3 and E)
Caspase-7 at symptomatic stages of the disease. AS = asymptomatic, BS =
Beginning of symptoms, ES = End-stage, Non-Tg = Non-trangenic animals M =
Month (Guegen et al, 2001; Guegen et al, 2002, Li et al, 2000).
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It should be mentioned that although multiple apoptotic downstream
factors have been implicated in ALS through expression analysis, no follow up
experiments deleting these genes in SOD1 mutant mouse models have been
published. Studies with administration of zVAD-fmk, a broad caspase inhibitor,
have shown delayed onset and extended survival in a mutant SOD1 mouse
model (Li et al, 2000), but there has been concern in the field whether this
inhibitor exhibits off-target effects. The only concrete evidence for endogenous
levels of apoptotic factors extending lifespan is the study deleting Bax in the
mutant SOD-1 trangenic line. Therefore, it is worth taking an in depth look at the
parameters examined in the Bax knockout of the SOD-1 transgenic animal.

Anatomical features of Bax deletion in the SOD1G93A mouse model
Current evidence in the field suggests that the apoptotic pathway is
involved in disease onset and progression of the SOD-1G93A ALS mouse model,
with deletion of Bax having the most dramatic effect in delaying disease onset
and extending lifespan. While knowledge that the apoptotic pathway plays a role
in progression of the disease is useful, it is also important to understand its role in
motor neuron degeneration at the anatomical level.
The main insight from this study is that the Bax KO/SOD1G93A transgenic
mouse line exhibits no reduction in motor neuron number at endstages of the
disease (Fig 1.10A, B), but axon degeneration is similar to that seen to the
SOD1G93A mouse model (Fig 1.10D, E) (Gould et al, 2006). It should be noted
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that both the motor neuron cell body somal size (Fig 1.10C) and axon diameter at
endstage (Fig 1.10F) were reduced in size. Gould et al concluded in this study
that while blocking the apoptotic pathway in this mouse model was able to rescue
motor neuron cell body loss, it was unable to rescue fibers from axon
degeneration. It is unclear whether the extension in lifespan was actually due to
the preserved cell body number at endstages of the disease or rather a delay in
axon degeneration.
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Figure 1.10 Anatomical features of the SOD-1G93A/Bax KO mouse line. A)
Representative images of motor neurons by vCHAT mRNA staining at P140 and
Endstage in a Bax WT and Bax KO (top row) and SOD-1 Tg/Bax WT and SOD-1
Tg/Bax KO (bottom row). Quantification of the B) number of lumbar motor
neurons and C) somal size of the motor neurons pictured in A. D) Representative
images of the ventral root in a Bax WT and Bax KO (top row) and SOD-1 Tg/Bax
WT and SOD-1 Tg/Bax KO (bottom row) with quantification of E) axon number
and F) axon diameter (Gould et al, 2006).
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While there is strong evidence for a role of the apoptotic pathway in ALS
mouse models, it is clear that ablating the apoptotic pathway is not sufficient to
prevent disease. All manipulations of the apoptotic pathway have merely delayed
onset and extended lifespan. Therefore, pathways other than apoptosis are likely
to be involved in ALS. This is not surprising, especially due to the lack of
apoptotic morphology of motor neurons seen in ALS patients and mouse models.
Careful studies have tracked the progression of anatomical features of the
disease as discussed above. It is therefore known that neuromuscular junction
denervation and axon degeneration precede motor neuron cell body loss (Fischer
et al, 2004) and that ablating the apoptotic pathway by a Bax deletion does not
affect axon degeneration. We therefore, hypothesized that other molecular
pathways that may play a role in neuromuscular junction denervation or axon
degeneration would make good candidates to pursue in this ALS mouse model.

The Wallerian degeneration pathway
The Wallerian degeneration pathway seemed a perfect candidate for two
reasons: (1) it is known to be independent of the apoptotic pathway (Whitmore et
al, 2003) and (2) it is known to play a role in axon degeneration in other motor
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neuron axonopathies (Ferri et al, 2003). Augustus Waller discovered Wallerian
degeneration in 1850 as a process where the distal portion of the axon
degenerates after insult or injury (Waller et al, 1850). The fortuitous generation of
the Wallerian degeneration slow (WldS) mouse helped elucidate this pathway as
an active degeneration process. In the WldS mouse, the distal axons that
normally degenerate, remain intact for up to two weeks after being severed away
from the cell body (Lunn et al, 1989, Tsao et al 1994).
The WldS gene has been shown to protect axons in many disease models
such as glaucoma, peripheral neuropathy, and motor neuron disease (Beirowski
et al, 2008; Ferri et al, 2003; Hasbani and O’Malley, 2006; Mi et al 2005; Sajadi
et al, 2004; Wang et al, 2002), but the role of WldS in ALS is unclear. Fischer et al
found that when the WldS mouse was crossed with the SOD1G93A mouse model,
there was increased survival compared to the SOD1G93A line (Fischer et al,
2005). However, Vande Velde et al, did not see any difference in survival in the
WldS/SOD1G37R or WldS/SOD1G85R mouse lines (Fig 1.11) (Vande Velde et al,
2004). It is unclear whether these conflicting results are due to the difference in
mutant SOD-1 transgenic lines tested, or whether there is ultimately no effect
caused by the WldS fusion protein.
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Figure 1.11 Conflicting results for the role of WldS in ALS. A) WldS/SOD1G93A
mice show increased survival compared to the SOD1G93A line. B) No extension in
survival is seen in WldS/SOD1G37R or C) WldS/SOD1G85R mouse lines. (Fischer et
al, 2005: panel A; Vande Velde et al, 2004: panel B, C).

The WldS gene encodes a chimeric fusion protein made up of the NAD
biosynthetic enzyme nicotinamide mononucleotide adenyl-transferase (Nmnat1),
which converts NAD+ from nicotinamide mononucleotide (NMN) and ATP, and a
fragment of the ubiquitination factor UBE4B (Conforti et al, 2000). The WldS
fusion protein allows for localization of nuclear Nmnat1 to the axon, and this has
been shown to impart the axon protective effect (Araki et al, 2004; Babetto et al,
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2010; Sasaki et al, 2009). This has been verified with direct transduction of
Nmnat1 protein into cut axons in vitro (Sasaki and Milbrandt, 2010) that can
rescue axon degeneration and resulting axon degeneration after depletion of
WldS protein from injured axons (Wang et al, 2015).
It is thought that Nmnat1 has its axon protective effect by substituting for
Nmnat2, which is normally present in the axon. Nmnat2 is supplied to the axon
by continual axonal transport and thus, is blocked after injury. While the function
of Nmnat2 in protecting axons after injury is not well understood, it is thought to
function as a “survival factor” where its removal leads to axon degeneration, in
uninjured or injured axons (Giley and Coleman, 2010).
Ultimately, the WldS fusion protein present in the mouse confers a gain-of
function process, overexpressing Nmnat1 in the axons of these animals. In
addition to this caveat, the protective effect of the WldS allele against Wallerian
degeneration is known to diminish with age (Gillingwater et al, 2002). For these
reasons, the WldS mouse model is not an ideal model for assessing the role of
Wallerian degeneration in ALS.
Multiple studies have followed up on the initial WldS result to try and
elucidate the mechanism of axon protection. A role for a new component in the
Wallerian degeneration pathway came from a genetic screen in Drosophila. A
mutation in dSarm showed delay in degeneration after axotomy of the olfactory
receptor neuron axons (Osterloh et al, 2012). Jing Yang, a post doc in our lab,
also showed that Sarm1 KO protected cortical and sensory axons from
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degeneration after injury in vitro. He also demonstrated that Sarm1 KO axons
were protected from NMJ denervation and axon degeneration after sciatic nerve
crush in vivo (Fig 1.12) (Osterloh et al, 2012).

A

B

Fig 1.12 Sarm1 KO protects against axon degeneration and NMJ
denervation. A) Sarm1 KO (bottom row) protects against axon degeneration
fourteen days after sciatic nerve crush (right two panels) compared to
degenerated axon in Sarm1 heterozygotes (top row). No axon degeneration is
seen in control uncut axons (left two panels). B) Sarm1 KO (bottom row) protects
against muscle denervation six days after sciatic nerve crush (right two panels)
compared to complete denervation in Sarm1 heterozygotes (top row). No NMJ
denervation is seen in control uncut axons (left two panels) (Osterloh et al, 2012).

We decided to address whether deletion of Sarm1 could protect against
axon degeneration in an ALS mouse model for several reasons. 1) Sarm1 was
identified to be an active executioner of Wallerian degeneration and and 2)
because the WldS mouse involves a gain-of-function mutation and is not an ideal
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model for studying the role of Wallerian degeneration as the protective effect of
the WldS allele against Wallerian degeneration diminishes with age (Gillingwater
et al, 2002).

Perspective and overview of thesis project
The overall goal of this project was to determine 1) the role of the
Wallerian degeneration pathway and 2) its interaction with the apoptotic pathway
in a mouse model of ALS. Establishment and characterization of a mouse model
overexpressing a mutant gene, SOD-1G93A, originally identified to cause familial
ALS in human patients, has allowed for a deeper investigation into the molecular
mechanisms governing ALS. Careful examination of this mouse model led to the
discovery of ALS as a ‘dying back’ axonopathy with neuronal distal regions such
as the NMJ and axon preceding the effect seen at the cell body.
The apoptotic pathway has already been identified to be involved in
disease onset, progression, and survival in an SOD1G93A mouse model of ALS
and was shown specifically to prevent motor neuronal cell body death, but had no
effect on axon degeneration. This led us to investigate other players that were
involved in NMJ denervation and axon degeneration, initial events in ALS. The
Wallerian degeneration pathway served as a great candidate since it already was
shown to be involved in other motor neuron diseases, had an effect on axon
degeneration and NMJ denervation after sciatic nerve crush, and is independent
of the apoptotic pathway. Initial experiments done in the lab knocking out Sarm1
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in an SOD1G93A mouse model showed no effect on survival, but did show a
difference in disease onset and progression of the disease (Fig 1.13).

A

B

Figure 1.13 SOD-1G93A Tg, Sarm1-/- has effect on disease progression, but
no effect on survival. A) Survival curve and B) disease progression of SOD1G93A Tg,Sarm+/+(black), SOD-1G93A Tg,Sarm+/-(blue) and, SOD-1G93A Tg,Sarm-/(red). Mice are given neurological score 2 when the hind limbs start to become
paralyzed (Data from Jing Yang).

Since Sarm1-/- animals did affect disease onset and progression in the
SOD1G93A mouse, we next wanted to analyze the effect Sarm1 was having on the
anatomical features of the disease. This project will explore the Sarm1-/- effect on
neuromuscular junction denervation, axon degeneration, and motor neuron cell
body death throughout disease progression. In addition to a closer histological
analysis of the SOD-1G93A Tg,Sarm1-/- phenotype, we also wanted to explore the

36

interaction between this pathway and the classical apoptotic pathway, an already
known regulator of disease progression and survival of the SOD1G93A mouse
model of ALS.
In Chapter 2, I will discuss the findings of disease onset, progression and
survival when blocking individually the apoptotic pathway and the Wallerian
degeneration pathway. I will then present the results of ablating both of these
pathways together, specifically in the SOD-1G93A Tg mouse model. We identified
that these pathways play distinct roles in disease onset and progression of the
disease and that they act additively to reduce symptomatic stages of the disease.
Chapter 3 explores the anatomical features of deleting each of these
pathways individually and in combination. Histology was performed to examine
neuromuscular junction denervation in different hindlimb muscles, motor axon
degeneration in the ventral root, and cell body loss in the spinal cord. The
histological results track closely with progression of the disease in the ALS
mouse model. I conclude with a discussion tying the disease progression and
histology results together.
Chapter 4 investigates the non-cell autonomous role that is thought to
occur in the mutant SOD-1 mouse model of ALS. Examination of this non-cell
autonomous effect is pursued through the in vitro approaches described
previously, specifically using SOD-1 Tg astrocyte conditioned medium and
microglial co-cultures with primary motor neurons to identify new factors and
elucidate more fully the role of the Wallerian degeneration pathway in motor
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neuron cell death. I conclude with a discussion of these results and suggestions
for future experiments.
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Chapter 2: Apoptosis and Wallerian degeneration affect
disease onset and progression
Rationale
Previous studies showed that deletion of apoptotic pathway components
slows disease progression in the SOD-1G93A Tg mouse model of ALS, specifically
exerting its effect on motor neuron cell bodies and not axon degeneration. This
led us to explore other potential pathways that might mediate axon degeneration
in this disease model, particularly the Wallerian degeneration pathway. We
further wanted to examine the interaction between these two pathways to
determine if they could act synergistically to affect disease.
To determine the role of these two pathways both individually and
together, we decided to track disease onset and progression closely through
daily monitoring of disease symptoms through a neurological scoring system.
This allowed us to resolve the individual role of each of these pathways in the
behavioral phenotype exhibited by these mice.

Bax, but not Sarm1 deletion extends survival of the SOD-1G93A Tg mouse
model
To determine the individual and collaborative roles of the Wallerian
degeneration and the classical apoptotic pathways in ALS, we assessed the
effects of Sarm1 and Bax on survival and disease progression in SOD-1G93A Tg
mice. We first tested SOD-1 copy number in all of the SOD-1 Tg animals and
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removed all animals out of the range of the recommended SOD-1 copy number
used by standard Jackson Laboratory protocols (Fig 2.1).

Range of ΔCT with
correct SOD-1 copy
number

SOD-1 transgene copy number

Mouse number

Figure 2.1 SOD-1G93A copy number analyzed by qPCR. SOD-1G93A Tg animals
were tested for transgene copy number using quantitative PCR. Four mice were
excluded from the analysis (indicated in red boxes) since they exhibited SOD-1
copy number outside the range of those allowed by Jackson mice protocol
standards.

Consistent with previous results, blocking the apoptotic pathway by
genetic deletion of Bax prolongs survival of SOD-1G93A Tg mice by ~20 days
compared to littermate controls (SOD-1G93A,Bax-/-:187 +/- 13 days ; SOD1G93A,Bax+/+: 168 days +/- 14 days , **p =0.0052). Blocking both the Wallerian
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degeneration and apoptotic pathways similarly extended lifespan, but offered no
additional extension over genetic deletion of Bax alone (SOD-1G93A,Bax-/-;Sarm1-/: 182 +/- 14 days; *p =0.0495). No effect on survival was observed in mice
lacking Sarm1-/- alone (SOD-1G93A,Sarm1-/-: 172 +/- 12 days, SOD1G93A,Sarm1+/+: 168 +/- 14 days). (Fig 2.2A).
Interestingly, body weight loss was significantly delayed in SOD-1G93A
Tg,Bax-/-;Sarm1-/- mice compared to SOD-1G93A Tg (SOD-1G93A: 156 days +/- 13
days, SOD-1G93A,Bax-/-:170 +/- 14 days; ***p =0.0006, SOD-1G93A,Bax-/-;Sarm1-/-:
182 +/- 14 days; ***p =0.0004) and SOD-1G93A Tg ,Bax-/- mice (*p=0.0435),
indicating that SOD-1G93A Tg,Bax-/-;Sarm1-/- animals are healthier for a longer
period of time, despite the fact that their lifespan is not extended relative to SOD1G93A Tg lacking only Bax-/- (Fig 2.2B).

Figure 2.2. Survival and body weight loss of SOD-1G93A Tg mice. (A) Survival
and (B) body weight loss of SOD-1G93A Tg (black), SOD-1G93A Tg,Bax-/Sarm+/+(blue), SOD-1G93A Tg,Bax+/+Sarm-/-(red), and SOD-1G93A Tg,Bax-/-Sarm-/(green). This color scheme will be used throughout all of the figures in this paper.
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In addition to tracking survival and body weight, we also performed a
rotorod behavioral assay to assess motor performance of these animals. We
performed the rotorod assay on a different cohort of animals because exercise is
known to affect disease onset and progression. Since the size of this cohort was
so large, we needed to modify the existing rotorod protocol in order to test all of
the mice. The rotorod behavioral assay is normally performed every other day for
the duration of the study. We decided to test each mouse monthly at different
timepoints including P50, P90, P120, P150, and P180. These timepoints included
asymptomatic, early stage symptomatic, and late stage symptomatic periods. We
needed to test how much training was necessary to achieve results that related
to motor function and not motor learning.
In order to do this, we had differently staged mice perform three days of
training on the rotorod. We also slightly modified the rotorod protocol so that mice
were exposed to a short training period before times were recorded. Our results
showed that while training on the rotorod did slightly increase overall time the
mice were able to stay on the rotorod, the significant decrease in time at late
stages was observed similarly after either one, two, or three days of training
(Figure 2.3A-C). This allowed us to use this newly developed protocol to measure
differences seen between genotypes. Unfortunately, we were unable to
distinguish a difference among genotypes (Fig 2.3D), most likely because the
timepoints at which the mice were tested were too far apart to catch any key
differences.
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A

B

D

C

Motor Performance

Time (seconds)

150

SOD-1 Tg
SOD-1 Tg/Bax KO
SOD-1 Tg/Sarm KO
SOD-1 Tg/dKO
WT
Bax KO
Sarm KO
dKO

100

50

0

P50

P90

P120

P150

P180

Age (Days)

Figure 2.3. Rotorod Behavioral Assay. A new training protocol was
developed to test the rotorod behavioral assay in mice. Mice at different ages and
disease stages were tested using this new protocol with A) 1 day of training, B) 2
days of training, or C) 3 days of training. The age of the mice and neurological
score is listed on the x-axis of the graph. S0 = Score 0, S1 = Score 1, ES2 =
early stage 2, S3 = Stage 3, LS2 = late stage 2. D) Rotorod performance of SOD1G93A Tg (black solid line), SOD-1G93A Tg,Bax-/-Sarm+/+(blue solid line), SOD-1G93A
Tg,Bax+/+Sarm-/-(red solid line), SOD-1G93A Tg,Bax-/-Sarm-/- (green solid line),
SOD-1WT (black dotted line) SOD-1WT,Bax-/-Sarm+/+ (blue dotted line), SOD1WT,Bax+/+Sarm-/- (red dotted line) and SOD-1WT,Bax-/-Sarm-/- (green dotted line)
animals at P50 (n=15 per genotype), P90 (n=12 per genotype), P120 (n=9 per
genotype), P150 (n = 6 per genotype) and P180 (n = 3 per genotype).
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Sarm1 involved in early stages and Bax involved in late stages of the
disease
Neurological scoring system guidelines from The Jackson Laboratory were
used to track symptom onset and disease progression in mice (Fig 2.4A). SOD1G93A Tg,Bax-/- and SOD-1G93A Tg,Bax-/-;Sarm1-/- mice remained symptom free for
significantly longer than SOD-1G93A Tg controls (SOD-1G93A: 143.8 +/- 5.26; SOD1G93A,Bax-/-:159.2+/-5.5 days, *p =0.0291; SOD-1G93A,Bax-/-, Sarm1-/-: 171.1+/4.91; **p =0.0016). Although Sarm1-/- does not prolong survival of SOD-1G93A Tg
ALS animals, disease onset and progression were modestly affected. SOD-1G93A
Tg, Sarm1-/- animals exhibit disease-associated symptoms (score 1: muscle
weakness) earlier than littermate controls (SOD-1G93A,Sarm1-/-: 132.8 +/- 7.74
days). (Fig 2.4B). However, progression to score 2 is delayed, thereby prolonging
the period that SOD-1G93A Tg, Sarm1-/- animals exhibit early disease symptoms
compared to SOD-1G93A Tg animals (SOD-1G93A: 18.33 +/- 3.091 days; SOD1G93A,Sarm1-/-: 37.55 +/- 7.056 days, * p =0.033). In contrast, progression from
score 1 to score 2 occurs more quickly in SOD-1G93A Tg, Bax-/-; Sarm1-/- animals
(SOD-1G93A Tg, Bax-/-; Sarm1-/- : 8 +/- 1.462 days, ** p =0.008) (Fig 2.4C).
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Genetic disruption of the Wallerian and apoptotic pathways also modifies
later stages of the disease. In SOD-1G93A Tg, Bax-/- mice, the length of time
between onset of score 2 to paralysis (ES) is significantly prolonged compared to
controls (SOD-1G93A: 6.56 +/- 1.69 days; SOD-1G93A,Bax-/-:12.91 +/- 1.84 days;
*p=0.022) (Fig 2.4D).

A

B

C

D

Figure 2.4 Disease onset and progression of SOD-1G93A Tg mice. (A)
Schematic of neurological scoring and corresponding disease stage of animal.
Mean number of days mice in each genotype (SOD-1G93A Tg (n=9), SOD-1G93A
Tg,Bax-/-Sarm+/+(n=11),
Tg,Bax-/-Sarm-/-(n=9))

SOD-1G93A
listed

above

Tg,Bax+/+Sarm-/-(n=9),
was

given

score

and
0

SOD-1G93A

and

termed

presymptomatic (B), given score 1 and termed as early stage (C), and given
score 2 or later and termed late stage (D).
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Elimination of both Bax and Sarm decreases symptomatic stages in ALS
Further, total disease duration was significantly reduced in the SOD-1G93A
Tg, Bax-/-;Sarm1-/- animals relative to other groups (SOD-1G93A: 26.67 +/- 3.44
days, SOD-1G93A Tg, Bax-/-, 26.90 +/- 4.829 days, ; SOD-1G93A,Sarm1-/-: 41.55 +/7.91 days SOD-1G93A,Bax-/-, Sarm1-/-: 13.56 +/- 2.28 days; *p =0.017, *p =0.029,
**p =0.002, respectively) (Fig 2.5A). The differences in disease progression that
are observed between Bax-/- and Sarm1-/- animals indicate that the apoptotic and
Wallerian degeneration pathways play parallel and synergistic roles in ALS (Fig
2.5B).

A

B

Figure 2.5 Duration and complete progression of SOD-1G93A Tg mice. (A)
Mean number of days spent in both early and late stage of disease which results
in total duration of symptomatic stages of the disease (B) Mean number of days
subset of animals in each genotype spent in each stage.
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Conclusions
Here we showed that the apoptotic pathway and Wallerian degeneration
pathway play distinct roles in disease onset and progression of the disease. By
tracking disease symptoms, we were able to show that the Wallerian
degeneration pathway through deletion of Sarm1 plays a role in symptom onset
of the disease, while the apoptotic pathway is involved more in late stages of the
disease. We also were able to show that the apoptotic pathway can delay
symptom onset, but does not decrease overall duration of the disease, whereas
deletion of Sarm1 does increase overall disease.
Interestingly, the neurological scoring and body weight loss results show
that the apoptotic and Wallerian degeneration pathways function additively to
control disease onset and progression, ultimately resulting in a decreased burden
of symptomatic stages of the disease and an extended survival that is
comparable to the individual deletion of the apoptotic pathway.
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Chapter 3: Histological analysis tracks with disease
Rationale
Since the Bax and Sarm genes were found to play distinct roles in disease
onset and progression, we next wanted to ask what the anatomical features
throughout disease progression were when deleting these genes, both
individually and together. We also wanted to determine how these histological
changes tracked with disease onset and progression.
Along with a general characterization of anatomical features throughout
the disease, we also were curious to investigate the role of each of these
pathways in the “dying back” progression of the disease. Previous results had
shown that deleting the apoptotic pathway resulted in preserved motor neuron
cell body loss, but no axon degeneration at endstages of the disease. We wanted
to perform a closer analysis at various timepoints to determine if this delayed
onset tracked with delayed early features of the disease, such as NMJ
denervation and axon degeneration. Furthermore, this is the first study to perform
careful histological characterization when deleting the Wallerian degeneration
pathway and with double deletion of both pathways.

Bax and Sarm1 play distinct roles in neuromuscular junction denervation
To determine how the Wallerian and apoptotic pathways affect
neuromuscular junction denervation in the SOD-1G93A Tg model of ALS,
gastrocnemius and tibialis anterior muscles were examined at different disease
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stages. Representative images are shown for the tibialis anterior (Fig 3.1) and
the gastrocnemius muscle (Fig 3.2). In SOD-1G93A Tg animals, NMJ denervation
was first observed at P90 and was nearly complete by disease endstage (Fig 3.1,
3.2, quantified in 3.3). Denervation of both muscles was significantly delayed at
P90 in both SOD-1G93A, Bax-/- and SOD-1G93A, Bax-/-, Sarm1-/- (Fig 3.1, 3.2, 3.3),
but only the tibialis anterior muscle showed delayed NMJ denervation in the
SOD-1G93A, Sarm1-/- mice at P90 (SOD-1G93A: 39.67 +/- 6.36 % innervated,
SOD-1G93A,Bax-/-: 100 +/- 0; ***p<.0001, SOD-1G93A, Sarm1-/-: 92.33 +/- 4.09,
***p<0.001; SOD-1G93A,Bax-/-, Sarm1-/-: 100 +/- 0; ***p<0.001 for tibialis anterior
and SOD-1G93A: 45 +/- 8.62 % innervated, SOD-1G93A,Bax-/-: 100 +/- 0;
***p<.0001, SOD-1G93A, Sarm1-/-: 37.33 +/- 1.202; SOD-1G93A,Bax-/-, Sarm1-/-: 100
+/- 0; ***p<0.001 for gastrocnemius).
At P120 and P150, the percentages of partially and completed denervated
NMJs were similar across all the genotypes for the gastrocnemius muscle (Fig
3.2, quantified in 3.3B). However, in the tibialis anterior, the number of fully
innervated NMJs was significantly increased in SOD-1G93A,Bax-/-, Sarm1-/- mice
compared to the SOD-1G93A Tg at P120 and P150 (Fig 3.1, 3.3A) (SOD-1G93A:
21.33 +/- 13.74 % innervated, SOD-1G93A,Bax-/-, Sarm1-/-: 53 +/- 0.58 at P120 and
SOD-1G93A: 13.67 +/- 0.89 % innervated, SOD-1G93A,Bax-/-, Sarm1-/-: 36.33 +/6.64 at P150).
In P90 SOD-1G93A; Sarm1-/- mice, NMJ innervation is preserved in the
tibialis anterior, but not the gastrocnemius muscle. Increased NMJ innervation
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was also observed in the SOD-1G93A,Bax-/-, Sarm1-/- tibialis at later time points
(P120 and P150). Denervation was decreased in SOD-1G93A,Bax-/-, Sarm1-/gastrocnemius muscle relative to the SOD-1G93A Tg, but the reduction was not
significant (Fig 3.2 and quantified in 3.3B).

Figure 3.1 Neuromuscular junction denervation of the tibialis anterior
muscle throughout disease progression. α-bungarotoxin was used to label
postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic sites
of the neuromuscular junction in the tibialis anterior (shown above). Yellow was
counted as completely innervated synapses, yellow and green (indicated by
white arrows) were counted as partially innervated synapses, and green only
were counted as denervated synapses. (A) SOD-1G93A Tg, (B) SOD-1G93A
Tg,Bax-/-Sarm+/+, (C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/Sarm-/- animals (n=3 for each timepoint) were dissected when each reached P50,
P90, P120, P150, and when they reached score 4, or endstage. Scale bar = 20
μm.
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Figure 3.2 Neuromuscular junction denervation of the gastrocnemius
muscle throughout disease progression. α-bungarotoxin was used to label
postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic sites
of the neuromuscular junction in the gastrocnemius muscle. Yellow was counted
as completely innervated synapses, yellow and green (indicated by white arrows)
were counted as partially innervated synapses, and green only were counted as
denervated synapses. (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C)
SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for
each timepoint) were dissected when each reached P50, P90, P120, P150, and
when they reached score 4, or endstage.
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Figure 3.3 Neuromuscular junction quantification of the tibialis anterior and
gastrocnemius muscle. Synapses from Fig 3.1 and 3.2 were quantified as
either innervated (yellow bars), partially innervated (grey bars) or denervated
(green bars) in the (A) tibialis anterior and (B) gastrocnemius in the SOD-1G93A
Tg (black font) SOD-1G93A Tg,Bax-/-Sarm+/+ (blue font), SOD-1G93A Tg,Bax+/+Sarm/-

(red font), and SOD-1G93A Tg,Bax-/-Sarm-/- (green font) animals (n=3 for each

timepoint) at P50, P90, P120, P150, and ES (endstage).
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Sarm1 deletion slightly delays axon degeneration in SOD-1G93A Tg
animals
Ventral root samples were analyzed to determine the effect of the
apoptotic and Wallerian degeneration pathways on axon degeneration. The
number of large and small diameter axons that were intact or degenerated was
quantified at different time points throughout the disease (Fig 3.4 and quantified
in 3.5). Large diameter axons first showed signs of degeneration by P120 in
SOD-1G93A controls, with a significant decrease in the number of intact axons by
P150 (Fig 3.5A). In SOD-1G93A,Bax-/-, Sarm1-/- mice, axon degeneration was
significantly delayed, as evidenced by an increase in the number of large
diameter axons at P150 (SOD-1G93A: 42.25 +/- 23.9 large axons, SOD-1G93A,Bax/-

, Sarm1-/-: 161.3 +/- 12.1 at P150; *p=0.03) (Fig 3.5A). Degeneration was also

modestly affected in SOD-1G93A,Bax-/- and SOD-1G93A, Sarm1-/- , but not
significantly.
By disease endstage, axons had degenerated to a similar extent across
genotypes. Consistent with a role for Bax in developmental cell death, the
number of small diameter axons was significantly increased in SOD-1G93A,Bax-/mice, and to a similar extent in SOD-1G93A,Bax-/-;Sarm1-/- animals at all ages. The
number of small diameter axons was modestly affected at disease endstage in all
mutants, but significantly in both SOD-1G93A,Bax-/- and SOD-1G93A,Bax-/-;Sarm1-/mice (Fig 3.5B). These results indicate that loss of motor axons in the ventral root
mostly reflects the loss of large diameter axons.
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Figure 3.4. Motor axon degeneration in ventral root. Representative electron
micrograph images taken of ventral root samples dissected from (A) SOD-1G93A
Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D)
SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for each timepoint) when each reached
P50, P90, P120, P150, and when they reached score 4, or endstage. Black
arrows indicate large degenerating axons. Scale bar = 5 μm.
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Figure 3.5. Quantification of large and small axons in ventral root. Intact
(black bars) and degenerated (gray bars) (A) large and (B) small diameter axons
were counted from SOD-1G93A Tg (black font) SOD-1G93A Tg;Bax-/-Sarm+/+ (blue
font), SOD-1G93A Tg;Bax+/+Sarm-/-(red font), and SOD-1G93A Tg;Bax-/-Sarm-/(green font) animals (n=3 for each timepoint) at P50, P90, P120, P150, and ES
(endstage).
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Deletion of Bax and Sarm1 delays large neuron loss in ventral horn
NeuN+ cell bodies were counted in the ventral horn of the spinal cord.
SOD-1G93A Tg animals first exhibit motor neuron loss at late stages (P150) and at
endstage, after NMJ denervation and axon degeneration (Fig 3.6A, 3.6E) as
reported (Fischer et al, 2004). As reported previously (Gould et al., 2006), the
ventral horn of SOD-1G93A, Bax-/- animals show an increase in neuron number
(SOD-1G93A: 50 +/- 1.0 NeuN+ neurons, SOD-1G93A,Bax-/-: 82.7 +/- 1.33 NeuN+
neurons at P50), reflecting both a lack of developmental neuronal cell death and
protection of neuronal cell body death at disease endstage (SOD-1G93A,Bax-/-:
82.7 +/- 1.33 NeuN+ neurons at P50, SOD-1G93A,Bax-/-: 88.33 +/- 1.76 NeuN+
neurons at endstage (ES) p=ns) (Fig 3.6B and quantified in 3.6E). Large cell
bodies in the ventral horn (>10μm in diameter), thought to be the more vulnerable
neuron population in ALS, were also quantified. Although it was not statistically
significant, a trend of large motor neuron loss was observed in the P150 SOD1G93A,Bax-/-mice (SOD-1G93A,Bax-/-: 27.7 +/- 1.20 large NeuN+ neurons at P50,
SOD-1G93A,Bax-/-: 23 +/- 3.22 large NeuN+ neurons at P150). Loss of large
neurons in SOD-1G93A,Bax-/- mice was comparable to the SOD-1G93A Tg mice at
endstage (Fig 3.6) (SOD-1G93A: 14.33 +/- 0.33 large NeuN+ neurons at ES; SOD1G93A,Bax-/-: 15.33 +/- 0.33 large NeuN+ neurons at ES). There was no change in
total NeuN+ neuron number in SOD-1G93A,Bax-/- mice at endstage, because the
supernumerary large neurons atrophied and became smaller.
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Numbers of ventral horn neurons were similar in SOD-1G93A,Sarm1-/- mice
and SOD-1G93A Tg animals at P50 (SOD-1G93A: 50 +/- 1.0 NeuN+ neurons; SOD1G93A,Sarm1-/-: 52.7 +/- 1.33 NeuN+ neurons) Ventral horn neuron loss (total
NeuN+ neurons and large neurons (>10μm)) was delayed in P150 SOD1G93A,Sarm1-/- mice relative to SOD-1G93A Tg animals, but neuron loss was similar
at endstage (Fig 3.6C, 3.6E, 3.6F) (SOD-1G93A: 34.33 +/- 4.096 NeuN+ neurons
at P150; SOD-1G93A,Sarm1-/-: 51.7 +/- 0.33 NeuN+ neurons at P150; * p = 0.02;
SOD-1G93A: 28.33 +/- 2.667 NeuN+ neurons at ES, SOD-1G93A,Sarm1-/-: 24.67 +/1.33 NeuN+ neurons at ES, p=0.36).
The last time point (endstage) was always measured when the animal
reached Score 4 (complete paralysis) and varied among genotypes. The SOD1G93A and SOD-1G93A,Sarm1-/- animals reached this stage around P165, whereas
the SOD-1G93A,Bax-/- and SOD-1G93A,Bax-/-;Sarm1-/- mice reached this stage
around P185. Thus, Sarm1-/- protection of both large and total ventral horn
neuron number at P150 is closer to the time when the animals reach Score 4,
suggesting that deletion of Sarm1 causes the late stage of the disease to
progress rapidly. This is consistent with the neurological scoring phenotype in
which the SOD-1G93A,Sarm1-/- animals get the disease later (Score 2) and
progress very rapidly to endstage (Fig 2.4B).

58

Figure 3.6. Neuron cell body loss in ventral horn of spinal cord.
Representative images of NeuN+ stained 12 μm spinal cord sections labeling cell
bodies in (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+, (C) SOD-1G93A
Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3 for each
timepoint) were dissected when each reached P50, P90, P120, P150, and when
they reached score 4, or endstage. Yellow dotted line indicates ventral horn
where cell bodies were counted and * indicates midline of spinal cord.
Quantification of (E) total NeuN+ neurons and (F) large NeuN+ neurons (>10 μm)
located in the ventral horn at timepoints listed above. Scale bar = 50 μm
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Deletion of Bax and Sarm1 delays loss of MMP-9+ neurons
MMP-9 is a marker for the type of large motor neurons most susceptible to
degeneration in ALS (Kaplan et al, 2014). MMP-9+ expressing neurons in the
SOD-1G93A animals degenerated at P120 (Fig 3.7A, quantified in 3.7E) (SOD1G93A: 4.65 +/- 0.43 MMP-9+ neurons at P50; SOD-1G93A: 2.08 +/- 0.63 MMP-9+
neurons at P120; * p = 0.05). Sarm1 knockout, and Bax;Sarm1 double knockout
protected MMP-9+ expressing ventral horn neurons up to P150 (Fig 3.7B-D) )
(SOD-1G93A: 1.51 +/- 0.44 MMP-9+ neurons; SOD-1G93A,Bax-/-: 3.07 +/- 0.70;
p=0.4 ; SOD-1G93A, Sarm1-/-: 3.28 +/- 0.06, *p=0.05; SOD-1G93A,Bax-/-, Sarm1-/-:
4.13 +/- 0.13 ; *p=0.03 at P150). MMP-9+ expressing neurons were lost similarly
in all genotypes at endstage (Fig 3.7E) (SOD-1G93A: 1.01 +/- 0.20 MMP-9+
neurons; SOD-1G93A,Bax-/-: 1.11 +/- 0.11; SOD-1G93A, Sarm1-/-: 1.00 +/- 0.17;
SOD-1G93A,Bax-/-, Sarm1-/-: 1.34 +/- 0.21 ; at ES).
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Fig 3.7. MMP-expressing neuron loss in the ventral horn of the spinal cord.
Representative images of MMP-9+ stained 12 μm spinal cord sections labeling
motor neuron cell bodies in (A) SOD-1G93A Tg, (B) SOD-1G93A Tg,Bax-/-Sarm+/+,
(C) SOD-1G93A Tg,Bax+/+Sarm-/-, and (D) SOD-1G93A Tg,Bax-/-Sarm-/- animals (n=3
for each timepoint) were dissected when each reached P50, P90, P120, P150,
and when they reached score 4, or endstage (ES). P50 and P150 representative
images are shown. (E) Quantification for MMP-9+ motor neurons in P50, P90,
P120, P150, and ES ventral spinal cords.
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Conclusions
The results of histological analysis in Bax-/- and Sarm1-/- animals tracked
closely with disease progression. Apoptotic and Wallerian degeneration
pathways played distinct roles in the dying back phenotype. Symptom onset did
not correlate strictly with the start of neuromuscular junction denervation, but
rather occurred about thirty days after the start of NMJ denervation. However,
delay in NMJ denervation did correlate with a delayed symptom onset.
Interestingly, the SOD-1G93A,Bax-/-Sarm1-/- animals showed improved
neuronal morphology phenotype in all parameters, including a delayed
denervation at the NMJ, delayed axon degeneration, and motor neuron cell body
preservation which aligned with a delayed symptom onset. These differences
were even stronger even further than the Bax-/- strain alone.
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Chapter 4: Non-cell autonomous SOD-1 toxicity
Rationale
In parallel with the in vivo studies described above, we also took an in vitro
approach to identify novel factors that might play a role in SOD-1-mediated cell
death and to elucidate further the mechanism of neuronal cell death observed in
vivo. We attempted to replicate the previously reported co-culture assay of WT
motor neurons and conditioned medium from mutant SOD-1 astrocytes. The goal
of this project was to 1) screen through other factors of the apoptotic pathway to
determine their role in motor neuron cell death and 2) elucidate further the
mechanism between the apoptotic and Wallerian degeneration pathway in vitro.

Co-culture of motor neurons and astrocytes
In order to screen through other potential players that were involved in
causing motor neuron cell death in this SOD-1-mediated toxicity assay, we
needed to first replicate the assay. I first dissected motor neurons from the E12.5
spinal cords of the Hb9-GFP mouse line and co-cultured them with astrocytes
(Fig 4.1A). I then treated WT primary motor neurons with collected conditioned
medium (CM) from either SOD-1G93A Tg astrocytes or Non-transgenic littermate
controls (Ntg). After 7 days in culture, I observed a small decline in motor neuron
number in cultures conditioned with SOD-1 Tg CM compared to Ntg conditioned
medium (Fig 4.1B)
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Fig 4.1 Motor neuron loss after treatment with SOD-1 astrocyte conditioned
medium. A) Motor neurons isolated from the HB9-GFP mouse line stained with
GFP (green) and HB9 antibody (red) co-cultured with an astrocyte monolayer,
stained with the marker astrocyte-specific marker, GFAP (blue). B) Motor neuron
number after 7 days cultured with either CM from non-transgenic Ntg astrocytes
(white bar) or SOD-1G93A Tg astrocytes, MN = motor neuron (black bar).

However, we found that not every Hb9-GFP expressing cell stained with
the Hb9 antibody (Fig 4.2A). This led to an investigation of the Hb9-GFP line that
we were using in the lab. Although Hb9 is a post mitotic marker of motor neurons,
we had discovered the Hb9-GFP line was not specific to motor neurons both by
observing E12.5 sections from spinal cord stained with Hb9 antibody and either
stained with GFP antibody (Fig 4.2B) or just looking at endogenous GFP (Fig
4.2C). This led us to try to determine a new marker for motor neurons. A marker
that labeled motor neurons more specifically was peripherin, which we showed
successful labeling both in vivo (Fig 4.2E) and in vitro (Fig 4.2F).
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Fig 4.2 Peripherin as a marker for motor neurons. A) Motor neurons
dissected and dissociated from spinal cords at E12.5 from the Hb9-GFP mouse
line. Circled motor neurons also labeled with the Hb9 antibody stain. B)
Unspecific staining of non motor neurons of E12.5 spinal cords in the Hb9-GFP
mouse line co-labeled with Hb9 and either GFP antibody (green) or C)
endogenous GFP. Serial sections of E12.5 spinal cord stained with D) Hb9 and
E) peripherin. F) Peripherin (green) and Tuj (red) staining in vitro.

Non-cell autonomous SOD-1 toxicity causes motor neuron cell death, but
not axon degeneration
Once we determined a marker for motor neurons in vitro, we attempted to
reproduce the SOD-1 Tg astrocyte-mediated toxicity of primary WT motor
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neurons (Nagai et al, 2007). We collected conditioned medium (CM) from both
SOD-1G93A Tg astrocytes and their nontransgenic littermate controls and placed
the CM on dissociated motor neuron cultures for 7 days. We saw a decline of
motor neuron number (i.e. peripherin+ neurons) conditioned with SOD-1G93A Tg
CM compared to WT CM (Fig 4.3A-C).
We next wanted to determine the effect of SOD-1G93A Tg CM on axon
degeneration since deletion of Sarm1 slightly delayed axon degeneration in vivo.
We utilized an assay using a spinal cord explant developed in the lab by Zhuhao
Wu. The ventral section of the spinal cord was isolated and allowed to adhere to
PDL/laminin coated cover slides. These explants grow their axons in a concentric
fashion. We treated these ventral explants with either WT or SOD-1 Tg CM. We
did not observe axon degeneration of the ventral explants cultured with SOD-1
Tg CM compared to WT CM either after 2 days (Fig 4.3D-E) or 7 days (data not
shown).
We next tried to co-culture microglia with the ventral explant cultures since
microglia were shown by others to cause more motor neuron death than either
the SOD-1 Tg astrocyte monolayer or CM (Nagai et al, 2007). We isolated
cortical microglia from P0 pups and allowed microglia to adhere for three to four
days before plating ventral explant cultures. Ventral explant cultures were grown
on microglia either isolated from SOD-1 Tg animals or littermate controls (WT) for
seven days. Axons from ventral explant cultures did not show any difference in
degeneration cultured with WT vs. SOD-1 Tg microglia (Fig 4.3 F & G).
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Fig 4.3 Mutant SOD-1 CM causes motor neuron cell death in dissociated
culture, but not ventral explant culture. Dissociated motor neurons labeled
with tuj (red) and peripherin (green) treated with CM from A) WT astrocytes or B)
SOD-1G93A Tg astrocytes. C) Quantification of motor neurons shows significant
loss of motor neuron number cultured with SOD-1 CM compared to WT CM. No
axon degeneration is seen in E12.5 ventral explants cultured with D) WT
astrocyte CM vs. E) SOD-1 astrocyte CM. No axon degeneration is seen in E12.5
ventral explants cultured with F) WT microglia vs. G) SOD-1 microglia.
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Conclusions
While we were able to replicate the cell death phenotype attributed by
SOD-1 Tg astrocyte conditioned medium, the effect was not robust enough to
identify novel factors. We sought an enhanced phenotype in ventral explant
cultures, specifically looking for an axon degeneration phenotype that we could
study in vitro. We were unable to observe any effect of either SOD-1 Tg
astrocyte-conditioned medium or microglia monolayers. These negative results
could have been caused by a number of different factors. For example,
astrocytes and microglia are not present in the peripheral nervous system and
therefore direct contact with these factors might not effect axon degeneration;
more natural sources of regulators would be Schwann cells.
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Chapter 5: Discussion and Future Directions
Before this study, there were conflicting reports as to the role of the
Wallerian degeneration pathway in mouse models of ALS. By deleting an active
executor of this pathway, Sarm1, we were able to definitively determine this
pathway’s role in a mouse model of ALS. This study answers whether deleting
the Wallerian degeneration pathway from the SOD-1G93A Tg mouse model would
extend lifespan as previously seen in the WldS/SOD-1G93A Tg mouse (Fischer et
al, 2004). We determined that knocking out Sarm1 and therefore ablating this
pathway does not further extend lifespan in an SOD-1G93A mouse model.
Therefore, the effect seen by WldS is likely caused by a gain of function
independent of Sarm1. Through careful characterization, we determined that the
Wallerian degeneration pathway plays a role in disease onset and progression.
In this study we completed a deeper analysis than had been done
previously on deleting the apoptotic pathway in the SOD-1G93A mouse model. We
were able to reproduce the previously reported results of cell body preservation
at endstage in the spinal cord, delayed neuromuscular junction denervation, and
extended lifespan (Gould et al, 2006). In addition to these results, we showed a
delayed onset in symptoms of the disease, a prolonged late stage of the disease,
and a specific loss of large axon and cell bodies at endstage.
This study is the first to show that deleting the Wallerian degeneration
pathway and the apoptotic pathway together resulted in an additive phenotype,
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more dramatic than deleting each of these pathways individually. We found
further delayed onset of symptoms, which tracked with histological effects
indicating delayed NMJ denervation, protection of axons at late stages of the
disease, and preservation of cell bodies at endstage. Most interestingly, all of this
resulted in a decreased duration of symptomatic stages of the disease.

The role of Sarm1 in the SOD-1G93A Tg model of ALS
In this study, we explored the role of the Wallerian degeneration pathway
and its interaction with the classical apoptotic pathway in a SOD-1G93A transgenic
ALS mouse model. Each of these pathways plays a unique role in disease
progression. Deletion of Sarm1 did not extend lifespan, but it did affect disease
onset and progression. SOD-1G93A Tg, Sarm1-/- mice tended to show trembling of
the hindlimbs during a tail suspension test (an early sign of the disease;
neurological score 1) before SOD-1G93A Tg animals. Combined with delayed late
stage development, this led to a prolonged duration of the early stage of the
disease in SOD-1G93A Tg, Sarm1-/- mice.
NMJ alterations present prior to symptom onset in the SOD-1G93A Tg
mouse line (Mancuso et al 2011; Casas et al 2013). NMJ denervation in the
tibialis anterior muscle is delayed in SOD-1G93A Tg, Sarm1-/- animals compared to
SOD-1G93A Tg animals. By P120, however, near the onset of symptoms, partial
and total denervation is similar. Therefore, it is not surprising that delayed NMJ
denervation in the tibialis does not track with symptom onset. There are two
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waves of denervation that occur: first, the fast fibers are denervated, followed by
a second wave of the more resistant fast fibers and some slow fibers (Hegedus
et al, 2007). Delayed denervation of the tibialis, but not the gastrocnemius,
suggests that deletion of Sarm1 may be protective for vulnerable fast fibers,
specifically intermediate type IID fast fibers, since there is a significantly
increased amount of these fibers in the tibialis compared to the gastrocnemius
(Allen et al, 2001).
The extended duration of the early phase is most likely due to delayed
axon degeneration in Sarm1 knockouts at late time points. It should be noted that
the number of animals in this cohort for each time point was small (n=3) and that
delayed axonal degeneration was seen in two out of the three animals. Axon
degeneration in one of the three P150 SOD-1G93A Tg, Sarm1-/- animals was
similar to the SOD-1G93A Tg animals, while the other two were intact. These
results point to P150 as a sensitive time point for axon degeneration in the SOD1G93A Tg ;Sarm1-/- and speaks to the rapid progression of axon degeneration in
these animals.
Sarm1-/- mice also showed a delayed ventral horn neuron cell body loss
compared to the SOD-1G93A Tg mice at P150. The dying back hypothesis
suggests that motor neuron cell death follows axon degeneration. Although
Sarm1 does delay ventral horn neuron cell body loss, it is possible that this
protection reflects delayed axon degeneration. This hypothesis seems likely
because (1) Sarm1 knockout delays axon degeneration in a number of different
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contexts and (2) ventral horn neuron cell body loss proceeds very quickly (P150 P165) in SOD-1G93A Tg, Sarm1-/- animals. Delayed NMJ denervation, axon
degeneration, and neuronal cell body loss, without an extension in lifespan
follows closely with the more rapidly progressing late phase seen in the SOD1G93A Tg, Sarm1-/- animals.

The role of Bax in the SOD-1G93A Tg ALS mouse model
We replicated results seen previously when blocking the apoptotic
pathway through a Bax deletion in the SOD-1G93A Tg mouse (Gould et al, 2006).
Lifespan of SOD-1G93A Tg animals was extended by ~20 days, NMJ denervation
was delayed, and an increased number of motor neuron cell bodies persisted
until endstage. That study was the first to identify the specific loss of large
diameter motor neuron axons and cell bodies and specific preservation of small
diameter motor neuron axons and cell bodies at endstage. The total number of
neuronal cell bodies did not decrease at endstage, whereas large ventral horn
NeuN+ cell bodies did. Thus, the ventral horn neurons remaining at endstage
included both pre-existing small diameter neurons and large diameter neurons
that atrophied and shrank in diameter. This suggests that although ventral horn
neuron cell bodies are protected by deletion of the apoptotic pathway, the
neurons that remain at endstage of the disease are most likely non-functional.
This interpretation is consistent with the fact that even though cell bodies remain
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in the SOD-1G93A Tg, Bax-/- animals, the animals still proceed through all stages of
disease progression, including complete paralysis.
The lifespan of SOD-1G93A Tg, Bax-/- animals correlates best with the
delayed disease onset, which likely reflects delayed NMJ denervation. Duration
of the disease is similar in SOD-1G93A Tg, Bax-/- and SOD-1G93A Tg animals (Fig
2.4A). We found that the late stage of the disease is significantly extended in the
SOD-1G93A Tg, Bax-/- compared to the SOD-1G93A Tg. One possibility is that this
extended late phase is due to an increased amount of collateral axonal sprouting.
Small fibers retain the ability to regenerate (Frey et al, 2000; Pun et al, 2006) and
SOD-1G93A Tg, Bax-/- mice have an increased number of small diameter axons,
which may be able to sprout and reinnervate the muscle. Therefore, we cannot
rule out the possibility that the NMJ phenotype observed in P90 SOD-1G93A Tg
;Bax-/- mice reflects reinnervation by an increased number of collateral axons
rather than delayed denervation. The reinnervation hypothesis may be a better
explanation for the prolonged late phase, but because these effects happen long
before disease onset, it is difficult to infer from these results which hypothesis is
correct.

The synergistic role of Bax and Sarm
Most interestingly, we were able to explore the synergistic role of both
these pathways in the SOD-1G93A Tg animal through a double genetic deletion of
Bax and Sarm1. Surprisingly, the SOD-1G93A Tg, Bax-/-Sarm1-/- was able to further
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delay disease onset significantly from both the SOD-1G93A Tg and more
interestingly, from the SOD-1G93A Tg, Bax-/- mice. The SOD-1G93A Tg, Bax-/-Sarm1/-

mice had an extended lifespan similarly to the SOD-1G93A Tg, Bax-/- mice (Fig

2.2A), but a duration of symptomatic stages that was half that of the SOD-1G93A
Tg and SOD-1G93A Tg, Bax-/- animals (Fig 2.4A). The delayed symptom onset
correlated with the delay in neuromuscular junction denervation similar to the
SOD-1G93A Tg, Bax-/- mice in the gastrocnemius and further in the tibialis anterior.
It is unclear at this time what the reason is for the further delay in denervation
attributed by Sarm1 deletion alone in the tibialis, but it is consistent with the even
greater effect seen in the Bax-/-Sarm1-/- mice in the tibialis.
Double knockout of Bax and Sarm1 delays large motor neuron axon
degeneration better than Bax or Sarm1 knockout alone. This likely reflects a Bax-/mediated delay in neuromuscular denervation and Sarm1-/- mediated axonal
protection. Small diameter ventral horn neuron cell bodies were equally well
protected in SOD-1G93A Tg, Bax-/-Sarm1-/- and SOD-1G93A Tg, Bax-/- mice at
endstage of the disease. It is worth noting that while not significant, P150 SOD1G93A Tg, Bax-/- mice had a trend towards a decreased number of large cell bodies
in the ventral horn. It seems, therefore, that the SOD-1G93A Tg, Bax-/-Sarm1-/- mice
had better protection of large cell bodies at this timepoint. If SOD-1G93A Tg, Bax-/and SOD-1G93A Tg, Bax-/-Sarm1-/- mice had been analyzed at another time point
closer to endstage, we may have been able to discern a difference in a ventral
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horn neuron cell body protection. All of these results are consistent with the more
rapidly progressing symptomatic stage seen in the SOD-1G93A Tg, Bax-/-Sarm1-/-.
These results support other groups’ findings of the importance of
denervation at the NMJ in the onset of ALS disease. Axon degeneration plays an
important role in disease progression and in determining lifespan. Ventral horn
neuron cell bodies can be preserved, even at endstage of the disease, whereas
axon degeneration always occurs. This points to the importance of determining
the underlying causes of neuromuscular denervation and axon degeneration.
Sarm1 was able to delay degeneration of the axon slightly, but its inability to
completely protect axons implies that other molecular pathways are involved in
axon degeneration in the SOD-1G93A Tg mouse model of ALS.

Future Directions
While this study elucidates the roles of Bax and Sarm1 genes in
phenotypic disease onset and progression as well as anatomical features of the
“dying back” of motor neurons in the SOD-1G93A mouse model, there are still
some outstanding questions in the field. These studies addressed the role of the
apoptotic and Wallerian degeneration pathways in this disease, but the cellular
site at which the genes act remains unknown. While it is thought that deleting
Bax and Sarm1 prevents neuronal cell death in a neuron specific manner, there
is also a known non-cell autonomous role of mutant SOD-1 in these mouse
models. The experiment to answer whether this effect occurs cell autonomously
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would be to knock out both of these genes conditionally in motor neurons using
either a Chat-Cre or Hb9-Cre mouse line. These experiments have obvious
limitations that crossing another allele would make getting the number of mice
needed for statistical analysis challenging, however, this approach would answer
whether deletion of these two pathways exhibit its effects in a cell autonomous
manner.
Also, in addition to the histological characterization that was already done,
further experiments would be able to answer what is occurring on a finer scale in
the ventral root and neuromuscular junction synapses. With the current results,
we are unable to determine the effect of deleting the apoptotic and Wallerian
degeneration pathways on reinnervation at the NMJ. Electron micrograph
analysis at the neuromuscular junction would answer which of the synapses are
reinnervated. Since this balance of denervation/reinnervation of synapses at the
NMJ regulates symptom onset, it is possible by enhancing reinnervation, one
could delay symptom onset further. Targeting this mechanism might be another
potential way to mitigate disease symptoms.
Another experiment to do would be to look at the later time points (around
P170-180) in the Bax-/- and Bax-/-/Sarm1-/- animals. It is likely, since the
histological analysis of Bax-/-/Sarm1-/- animals showed an even greater effect
compared to Bax-/- alone, that this later time point may show an even further
protection, specifically of large neurons and MMP-9 expressing cells in the
ventral spinal cord, and possibly even axons in the ventral root. Based on
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symptomatic stage data from the neurological scoring, it is likely that this late
time point would be a sensitive one for the Bax-/-/Sarm1-/- animals with either all
animals showing protection or a subset of them showing protection. Addressing
these questions would provide a clearer role for each of these pathways in the
mechanism of the ‘dying back’ nature of motor axons in the SOD-1G93A mouse
model of ALS.
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Chapter 6: Materials and Methods
Animal models
All experiments using animals were performed in accordance with NIH guidelines
and approved by the Institutional Animal Care and Use Committee at the
Rockefeller University. Mice null for Bax (Knudson et al, 1995) and SOD-1G93A Tg
mice (B6.Cg-Tg(SOD1-G93A)1Gur/J) were obtained from The Jackson
Laboratory. SOD-1G93A mice expressed a high copy number of the human SOD-1
gene, which harbors a glycine to alanine mutation at the 93rd codon of the SOD-1
gene. Bax-/- and Sarm-/- mice were mated to generate Bax+/-/Sarm+/- females. The
Bax/Sarm heterozygotes were then cross with Tg[SOD-1-G93A] male mice to
yield the following genotypes for analysis: SOD-1WTBax+/+,Sarm+/+; SOD-1WT Bax/-

,Sarm+/+; SOD-1WTBax+/+,Sarm-/-; SOD-1WTBax-/-,Sarm-/-; SOD-1G93A

Tg,Bax+/+,Sarm+/+; SOD-1G93A Tg,Bax-/-,Sarm+/+; SOD-1G93A Tg,Bax+/+,Sarm-/- and
SOD-1G93A Tg,Bax-/-,Sarm-/-. All comparisons in this study were between
littermates and housed together to minimize environmental factors. Mice were
genotyped using PCR protocols from the Jackson Laboratory. The mice were
housed with free access to water and SulfaTrim rodent chow. The mice were
divided into two cohorts. One was dedicated to determining survival, symptom
onset and progression through neurological scoring, body weight loss, and
endstage histology. The other was used for histological analysis at various time
points during disease progression: P50, P90, P120, and P150.
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Table 6.1 Genotypes analyzed in this study:
Genotype:
SOD-1WTBax+/+Sarm+/+

SOD-1G93A Tg; Bax+/+Sarm+/+

SOD-1WTBax-/-Sarm+/+

SOD-1G93A Tg; Bax-/-Sarm+/+

SOD-1WTBax+/+Sarm-/-

SOD-1G93A Tg; Bax+/+Sarm-/-

SOD-1WTBax-/-Sarm-/-

SOD-1G93A Tg; Bax-/-Sarm-/-

Survival, symptom onset, ALS disease progression
Survival, symptom onset, disease progression, and body weight loss were
assessed in one cohort (n= 8-9 for each genotype; 8 different genotypes listed
above). Symptom onset and disease progression were assayed using the
neurological scoring system guidelines from The Jackson Laboratory
(http://jackson.jax.org/rs/444-BUH-304/images/Working_with_ALS_Mice.pdf).
Mice were assessed by two experimenters every other day starting at P50 for the
duration of their lifespan. Mice were scored as follows: Score 1: trembling of the
hind legs during a tail suspension test; Score 2: toes curl under foot during
walking; Score 3: hind limb paralysis; Score 4: terminally paralyzed (unable to
right themselves after 30 seconds of being placed on each side). Animals were
euthanized upon reaching score 4. Body weight measurements were collected
daily beginning at P50 and through score 4 for mice carrying the SOD-1G93A allele
or until P200 for SOD-1WT controls.
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Rotorod behavioral assay
Motor performance of mice was tested using the rotorod behavioral assay. A
modified protocol was created and tested to accommodate a large cohort. Each
mouse was tested when they reached P50, P90, P120, P150 and P180. This
cohort was also used for histological analysis, so three mice were removed at
each timepoint resulting in P50 (n = 15 per genotype), P90 (n = 12 per genotype),
P120 (n = 9 per genotype), P150 (n = 6 per genotype), and P180 (n = 3 per
genotype). The modified protocol to test the behavioral function was to (1) place
the mice on the rotorod at a non-accelerating speed until each mouse stayed on
successfully for 1 minute, (2) run three trials with an acceleration of 5 RPM, (3)
give the mice a 1 minute break, and (4) run three trials with an acceleration of 5
RPM and record these three times. The average of the three trials was plotted for
each mouse.

Tissue collection
Mice were anesthetized and perfused with PBS followed by 4%
paraformaldehyde-PBS. For cohort 1, SOD-1G93A Tg mice were euthanized when
they reached score 4 and SOD-1WT animals were euthanized at P200 to
represent endstage. A second cohort was used to collect histological samples at
P50, P90, P120 and P150 (n=3 per time point per genotype). Whole mice were
placed on ice for 20 minutes after perfusion for further fixation. The sacral spinal
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cord, sacral ventral root, tibialis anterior and gastrocnemius muscles were
dissected and postfixed.

Neuromuscular Junction Analysis
Following dissection, the gastrocnemius and tibialis anterior muscles were
postfixed in 4% paraformaldehyde-PBS overnight, then washed 3x with 1x PBS
and transferred to a 2:1 OCT:30% sucrose-PBS solution for 3 days. Samples
were frozen in OCT using an isopropanol/dry ice bath and the cryopreserved
samples were sectioned longitudinally (80 μm). The tissue was permeabilized in
1% Triton X-100/PBS for 1 hour and then blocked overnight in 0.1% Triton X100/PBS containing 10% donkey serum at 4°C. Muscles were stained with rabbit
anti-synapsin (1:200, Synaptic Systems) in blocking buffer at 4°C for at least 24
hours. After four 1-hour washes using 0.1% Triton X-100/PBS, muscles were
incubated with donkey anti-rabbit Alexa 594 antibody (1:1000, Invitrogen) and αbungarotoxin, fluorescin conjugated (1:1000, Invitrogen) for 24 hours. Sections
were then washed in PBS four times and coverslips were mounted using
Fluromount-G (SoutherBiotech). Imaging of samples was performed with a LSM
510 laser scanning confocal microsome (Leica). To analyze presynaptic
terminals, maximum-intensity projections of z-stack images for each muscle
sample were generated using FIJI software. Postsynaptic AChR (α-bungarotoxinpositive) sites not apposed by synapsin were counted as denervated. Synapses
with less that 50% overlap were described as partially denervated. Approximately
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100 neuromuscular junctions were examined for both gastrocnemius and tibialis
anterior muscles for all time points and genotypes.

Axon counts and electron microscopy
Ventral roots were stored in 4% paraformaldehyde/2.5% glutaraldehyde in 0.1 M
sodium cacodylate buffer overnight at 4°C. Subsequently, the samples were
post-fixed in 1% osmium tetroxide for one hour on ice, stained with 1% Uranyl
acetate for 30 minutes at room temperature, dehydrated with increasing
concentrations of ethanol, and infiltrated/embedded in Eponate12 resin. Ultrathin
70 nm sections were cut and examined no the electron microscope (100CX
JEOL, Tokyo, Japan) at 80 kV with a digital imagin system (XR41-C, Advantage
Microscopy Technology Corp, Denver, MA). For quantification, large and small
diameter axons were counted as either intact or degenerated if any sign of
fragmentation was observed.

Neuron number in the ventral horn of the spinal cord
The sacral level of the spinal cord was fixed overnight in 4% paraformaldehyde1XPBS solution. Samples were then washed 3x with PBS and transferred to a
2:1 OCT:30% sucrose/PBS solution. Spinal cords were frozen in OCT in an
isopropanol/dry ice bath and then sectioned into 12 μm thick sections. Spinal
cord sections were stained with antibodies: mouse anti-NeuN (1:1000,
Chemicon) and goat anti-MMP-9 (1:200, Sigma-Alrich). The average number of
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NeuN+, large NeuN+ (>10μm) and MMP-9+ expressing neurons in the ventral
horn of eight spinal cord sections per animal is reported.

Statistical analysis
Statistical significance of survival and body weight loss was determined using a
Log-rank test and is represented as median days of survival +/- SEM. A one-way
ANOVA statistical test was used to test differences between genotypes in the
duration of different stages of the disease, neuromuscular junction innervation
(comparing different genotypes at various timepoints), and large and small axon
number (comparing genotypes at various timepoints). A one-way ANOVA
statistical test was used to determine differences in neuron number (NeuN+,
large NeuN+, and MMP-9+) within one genotype at the different timepoints.

Table 6.2 Antibodies used in this study

Antibody

Source

Rabbit anti-synapsin

Synaptic systems

Alexa 488-conjugated a-bungarotoxin

Invitrogen

Mouse anti-NeuN

Chemicon

Goat anti-MMP-9

Sigma Aldrich

Rabbit anti-peripherin

Millipore
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Mouse anti-tuj

Invitrogen

Mouse anti-GFAP

Millipore

Rabbit anti-GFP

Abcam

Rabbit anti-HB9

Sam Phaff

Primary astrocyte culture
Glial monolayers were prepared from SOD-1G93A Tg or their nontransgenic
littermate (WT) cortex P0 pups. Cortices were triturated 20-25x with a pipetman
to cells were plated in glial medium: DMEM (Invitrogen) containing 10% FBS
(Invitrogen) and 100 U of penicillin and streptomycin antibiotics (Invitrogen). Cells
were allowed to grow for ~2 weeks to reach confluency.

Astrocyte conditioned medium
After glial cells became confluent, cells were shaken for 1 hour at room
temperature at 100 rpm to remove microglia. The supernatant was then removed
and replaced with motor neuron cell medium. At 7 days, we collected the
conditioned medium, centrifuged it for 1000g for 5 minutes to eliminate floating
cells. The conditioned medium was filtered and frozen down at -80°C. Before use
on motor neurons, penicillin/streptomycin/glutamine plus cocktail of trophic
factors was supplemented into the conditioned medium.
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Primary motor neuron culture
Spinal cords from E12.5 WT CD-1 mice or HB9-GFP1 Tmj transgenic mice were
dissected from embryos in Hibernate-E medium. Spinal cords were trypsinized
with 0.05% trypsin (Invitrogen) for five minutes, run through 4% filtered BSA
cusion at 500 rpm for 5 minutes, centrifuged through a 5.2% sucrose gradient
made with optiprep solution in 4.4% Tricine buffer for 15 minutes at 800 rpm. The
cells were then washed once with neurobasal medium (Invitrogen) and spun
down at 1000 rpm for 5 minutes. The supernatant was removed and cells were
resuspended in motor neuron medium containing B27,
penicillin/streptomycin/glutamine, and a cocktail of neurotrophic factors including
10 ng/mL of brain-derived neurotrophic factor, 10 ng/mL of glia-derived
neurotrophic factor, 10 ng/mL of NT-3, and 25 ng/mL of ciliary neurotrophic
factor. Motor neurons were plated on plastic 8-well slides at 1500 cells/cm2
coated with poly-D-lysine/laminin.

Ventral explant cultures
Spinal cords from E12.5 WT CD-1 mice were dissected carefully out of the
embryo in Hibernate-E medium. The spinal cords were cut along the dorsal horn
so as to flatten out the spinal cord. The dorsal section of the spinal cord was then
cut from the ventral section of the spinal cord. The ventral spinal cord was then
cut into 8 even sections horizontally and each section was cut another 8 times
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horizontally and vertically. These ventral explants were then plated on plastic 8well slides coated in poly-D-lysine/laminin.
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Appendix 1: SOD-1WT Histology
In parallel with all of the SOD-1 Tg histological samples that were
collected, control SOD-1WT samples were also collected at the neuromuscular
junction, ventral root, and spinal cord at all of the different timepoints analyzed
above (P50, P90, P120, P150, and ES). Representative images of endstage
SOD-1WT and SOD-1G93A Tg animals and quantification of innervated synapses is
shown in A1.1. Motor axons in the ventral root at each timepoint are shown in
A1.2 and neuron cell body number is shown in A1.3 and A1.4.
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Figure

A1.1.

Neuromuscular

junction

innervation

at

endstage.

Representative images of neuromuscular junction of ventral root samples
dissected from SOD-1WT, SOD-1WT,Bax-/-Sarm+/+, SOD-1WT,Bax+/+Sarm-/-, and
SOD-1WT,Bax-/-Sarm-/-, SOD-1G93A Tg, SOD-1G93A Tg, Bax-/-Sarm+/+, SOD-1G93A
Tg, Bax+/+Sarm-/-, and SOD-1G93A Tg, Bax-/-Sarm-/- animals (n=3 for each
timepoint) at endstage (P200 for SOD-1WT animals and when the animals
reached score 4, or paralysis for SOD-1 Tg animals). α-bungarotoxin was used to
label postsynaptic sites (green) and synapsin antibody (red) labeled presynaptic
sites of the neuromuscular junction in the gastrocnemius muscle. Yellow was
counted as completely innervated synapses, yellow and green (indicated by
white arrows) were counted as partially innervated synapses, and green only
were counted as denervated synapses.
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Figure A1.2. Motor axon degeneration in ventral root. Representative
electron micrograph images taken of ventral root samples dissected from (A)
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD1WT,Bax-/-Sarm-/- animals (n=3 for each timepoint) when each reached P50, P90,
P120, P150, and P200 (ES).
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Figure A1.3. Neuron cell body in ventral horn of spinal cord. Representative
images of NeuN+ stained 12 μm spinal cord sections labeling cell bodies in (A)
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD1WTg,Bax-/-Sarm-/- animals (n=3 for each timepoint) were dissected when each
reached P50, P90, P120, P150, and P200, or endstage. Quantification of (E) total
NeuN+ neurons and (F) large NeuN+ neurons (>10 μm) located in the ventral
horn at timepoints listed above.
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Figure A1.4. MMP-9+ cell body in ventral horn of spinal cord. Representative
images of MMP-9+ stained 12 μm spinal cord sections labeling cell bodies in (A)
SOD-1WT, (B) SOD-1WT,Bax-/-Sarm+/+, (C) SOD-1WT,Bax+/+Sarm-/-, and (D) SOD1WTg,Bax-/-Sarm-/- animals (n=3 for each timepoint) were dissected when each
reached P50, P90, P120, P150, and P200, or endstage. (E) Quantification of
MMP-9+ neurons .
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Appendix 2. MMP-9+ cells at all timepoints in SOD1G93A Tg animals
MMP-9 labeled cells were shown for P150 and endstage timepoints in the
results section of this thesis to indicate the latest timepoint that showed
protection in Bax KO, Sarm KO, and Bax/Sarm dKO lines. Shown below are all of
the other earlier timepoints that showed protection (P50, P90, and P120). All
results in A2.1 showed similar protection at these timepoints comparatively to the
P150 timepoint in the genetic knockouts.
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Figure A2.1. MMP-9+ cell body in ventral horn of spinal cord. Representative
images of MMP-9+ stained 12 μm spinal cord sections labeling cell bodies in (A)
SOD-1G93A Tg, (B) SOD-1G93A Tg, Bax-/-Sarm+/+, (C) SOD-1G93A Tg, Bax+/+Sarm-/-,
and (D) SOD-1G93ATg, Bax-/-Sarm-/- animals (n=3 for each timepoint) were
dissected when each reached P50, P90, P120, P150, and endstage.
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Appendix 3. Treatment of infection with antibiotics
In the middle of the study we were conducting, we noticed something odd
occurring. The mice that contained the SOD-1G93A transgene were dying earlier
than their expected lifespan of ~P165 and they were progressing very rapidly
from Score 2 to Score 4, irrespective of genotype (Figure A3.1). This
phenomenon was ensuing with all animals that reached late stage, while WT
animals were unaffected. Blood samples were collected and pathological
analysis was done on these mice that died early. No extreme abnormalities were
discovered from this analysis.
We decided that it was possible that the mice may be harboring some sort
of infection, so we treated the mice with broad-spectrum antibiotics. The problem
resolved itself in mice treated with two weeks of SulfaTrim rodent chow. All mice
without two weeks of treatment were removed from the analysis and some mice
from Cohort 2 were added to this cohort to compensate for the loss of mice.
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Figure A3.1 Abnormalities in disease progression of SOD-1G93A Tg animals.
A) Time when mice reached neurological score 2 and B) reached score 4, the
phenotype at which they were sacrificed. SOD-1G93A Tg animals (black line)
(n=3), SOD-1G93A Tg/Sarm KO (green line) (n=2), and SOD-1 Tg/Bax KO/Sarm
KO (red line) (n=1). Survival of mice correlated with onset of Score 2.
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